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ABBREVIATIONS USED
USG –  Ultrasonogram
LSCS –  Lower Segment Cesarean Section
TXA -  Tranexemic Acid
MDG - Millenium Development Goal
BMI - Body Mass Index
PIH - Pregnancy Induced Hypertension
PPH -  Post Partum Hemorrhage
BP -  Blood Pressure
PR - Pulse Rate
RR - Respiratory Rate
Hb - Hemoglobin
PT -  Prothrombin Time
aPTT -  Activated Partial Thromboplastin Time
QBL -  Quantification of Blood Loss
DIC -  Disseminated Intravascular Coagulation
IUD - Intra Uterine Death
WHO - World Health Organization
ACOG -  American College of Obstetrics & Gynaecology
RCOG -  Royal College of Obstetrics & Gynaecology
BMI - Body Mass Index
AMTSL - Active Management of Third Stage of Labour
POD - Post Operative Day
PD -  Placental Delivery
EOS - End of Surgery
PP - Post Partum
NICU - Neonatal Intensive Care Unit
HMD - Hyaline Membrane disease
TTN -  Transient Tachypnea of Newborn
HIE -  Hypoxic Ischemic Encephalopathy
DVT - Deep Vein Thrombosis
MMR -  Maternal Mortality Rate
RBC - Red Blood Corpuscles
PL -  Previous LSCS
PROM -  Premature Rupture of Membrane
FD -  Fetal Distress
FI -  Failed Induction
CPD -  Cephalo Pelvic Disproportion
GHD -  Gestational Hypertension
FDP - Fibrin degradation Products
1INTRODUCTION
Caesarean section(CS) is found to be one of the most commonly
performed abdominal surgery on women in most part of the world. CS
was performed by Bennett in 1794 on his wife Elizabeth and first modern
CS was performed by a German Dr. Ferdinand Adolf Kehrer1
Though WHO had at one point of time, in 19822 stated that “there
is no justification for any region to have more than 15%” caesarean
section rate, they subsequently withdrew their statement in 2010. There is
no empirical evidence for an optimum percentage. What matters most is
that women who need CS should receive it.
 In recent years the CS rate is on increasing trend in both developed
countries and developing countries.  It has increased in USA from being
20 % in 1996 to 33 % in 2011.
The  Cesarean  percentage  is  46  %  in  China  and  40  %  in  Italy.
Similar trends have also been documented in low income countries,
particularly in Latin America and some countries in Asia3.
Delivery by CS when compared to vaginal delivery has more
complications both to mother and baby and the most important one is
primary and secondary post partum hemorrhage. This may result in
increased maternal mortality and morbidity.
2Today even though the CS is safer with improved surgical and
anesthetic techniques but it still remains the major cause of intra
operational and post operational complications – hemorrhage, infection,
and prolonged hospital stay than normal vaginal delivery4
PPH accounts for about 35% global maternal death. The MDG5
Goal to improve Maternal health targets to decrease maternal mortality by
75% by 2015. Every year 3.5 to 5 lakhs females die from pregnancy
related causes and 15 to 20 million females suffer morbidity attributed to
pregnancy.
Cesarean delivery when compared to vaginal delivery is more
traumatic because of tissue injury but is more preferred over vaginal
delivery in needed situation  to reduce the maternal and child mortality
and morbidity.  Hence there must be an appropriate balance between the
coagulation cascade system that provide clot formation and fibrinolytic
system that dissolves the clot6 .
Blood loss in CS about double than that lost in vaginal delivery.
During placental delivery there will be activation of fibrinolytic system
and last for 6 to 10 hrs thus resulting in Post Partum Hemorrhage. As a
result it is important to reduce the bleeding in cesarean section both intra
operatively and post operatively so as to reduce maternal mortality.
Excessive bleeding will make the need for transfusion of blood
products which make the prone to risk of transfusion related
3complications and adverse reactions ranging from mild febrile illness to
life threatening hemolytic reactions – TRALI (transfusion associated lung
injury).7
In taking into account of safety and cost effectiveness in respect to
blood bank operation and its shortage have made us to take effort to
reduce transfusion requiring during CS surgery.
As the fibrinolytic system is being activated from the time of
placental delivery an anti fibrinolytic agent – TRANEXEMIC ACID will
be effective in controlling the blood loss during CS. As its anti
fibrinolytic activity lasts for 6 – 10 hrs it can also control post partum
blood loss too.
In our study, the efficacy of Tranexemic Acid has been
investigated in reducing blood loss during and after cesarean section.
4AIMS OF THE STUDY
1. To find whether tranexamic acid is effective in reducing
peroperative and postoperative blood loss in lower segment
caesaerean section
2. To find whether tranexamic acid is associated with any adverse
reactions or complications
5OBJECTIVES OF THE STUDY
1. To study the effect of Intravenous infusion of Tranexemic Acid,
starting from 15 minutes prior to Skin Incision at the dose of 15
mg/Kg  Body  Weight,  in  study  group  and  compare  this  with  a
control group of same number who did not receive this drug
2. To study the following parameters in both groups to make sure that
the randomization has been proper and both groups are comparable
a. (I) Age
b. (II) Body Mass Index (BMI) which is calculated by
measuring
i. Weight
ii. Height
c. (III) Parity
d. (IV) Indication for Cesarean Section
e. (V) Duration of Cesarean Section
f. (VI) Birth weight of Baby
3. To study the following parameters in both groups and find whether
there is any change in
6a. Pre Op and Post Op Vital Parameters between the Study
Group and Control Group which is assessed by comparing
i. (VII) Pulse
ii. (VIII) Systolic BP
iii. (IX ) Diastolic BP
iv. (X) Respiratory Rate
b. Blood Loss between the Study Group and Control Group
which is assessed by comparing
i. (XI) Blood Loss during and following Cesarean
Section which is the sum of Per Operative Blood Loss
(from the time of Placental Delivery to End of
Surgery) and Post Operative Blood Loss (from End of
Surgery to 2 hours Post Partum)
ii. (XII) Fall in Hb % by comparing Hb % on Admission
and Hb % on 3rd Post Op Day
c. Complications of Cesarean Section between the Study Group
and Control Group which is assessed by comparing
i. (XIII) Incidence of PPH
7ii. (XIV) Need of Maternal Need of Maternal Blood
Transfusion
iii. (XV) Use of Additional Uterotonics
iv. (XVI) Prolonged Hospital Stay
d. Neonatal Outcome between the Study Group and Control
Group which is assessed by comparing
i. (XVII) APGAR
ii. (XVIII) Admission Rate in NICU
4. To find whether there are any Adverse Effects of Drug which is
studied by comparing the incidence of following between the Study
Group and Control Group
i. (XIX) Nausea
ii. (XX) Vomiting
iii. (XXI) Diarrhea
iv. (XXII) Thrombosis
8REVIEW OF LITERATURE
Obstetric hemorrhage is the leading cause of maternal death
worldwide. Approximately one maternal death due to postpartum
haemorrage occurs in every  7 minutes. PPH is a preventable factor.
During  placental  delivery there will be activation of fibrinolytic  system
. This  fibrinolytic activation will last upto  6  to 10  hours  resulting in
PPH.
Tranexamic acid  ,an antifibrinolytic drug  exerts its antifibrinolytic
activity  by blocking the lysine binding sites  of plasminogen  & the
plasmin molecules,thereby  preventing binding of  plasminogen and
plasmin to the fibrin substrate.Also tranexamic acid  inhibits plasminogen
activators so that inhibiting the conversion of plasminogen to plasmin.
 cesarean delivery when compared to vaginal delivery is more
traumatic and also mortality and morbidity  in caesarean delivery is
higher compared to vaginal delivery.
A study  conducted in india in 2010 (Mukerji et al) 8an analytical
observational study on maternal mortality and caesarean section reported
that there is  3 fold  risk of maternal  death after caesarean  section when
compared to vaginal delivery.
9In another study by  Bruinse et al9 , Gurbuz B  et al 10reported that
emergency peripartum hysterectomy is about  5   to  10  times after
caesarean section than  vaginal  delivery.
Taking all this into account and since prevention is better than cure
we decided   to use Tranexamic acid in our trial.
COAGULATION AND FIBRINOLYTIC CASCADE
Haemostasis is an appropriate balance between coagulation
cascade and fibrinolytic system that produces fibrin clot and dissolution
of  the fibrin clots respectively.
When there is any tissue injury there will be activation of
coagulation system in which the primary response will be the platelet
plug formation by the activation and aggregation of platelets. The second
response will be formation of thrombin, which in turn cleaves the
fibrinogen into fibrin monomers. They polymerise to form insoluble
fibrin thus forming a haemostatic seal on damaged blood vessel wall11
By the deposition of fibrin the fibrinolytic system gets activated
and helps in keeping the vessel lumen open. When the plasminogen gets
trapped within the clot it binds with lysine residues on the surface of
fibrin and it gets converted into active plasmin by an activator released
from the endothelial cells known as tissue plasminogen activator t-PA.
10
Thus the activated plasmin degrades the fibrin into large fragments,
these fragments are further degraded into fibrin degradation products
(FDP) and are removed in the circulation.
Hyperfibrinolysis is found to be associated with inflammatory and
allergic states since the inflammatory and fibrinolytic systems are inter
related in the generation of proinflammatory cytokines. But fibrinolysis is
naturally regulated by plasminogen activator inhibitors (PAI-1) and
plasmin inhibitor(?2 antiplasmin)
Hyperfibrinolysis which due to rapid dissolution of haemostatic
fibrin results in recurrent and excessive bleeding that can be prevented by
antifibrinolytic drugs which stabilize the fibrin clots by blocking the
action of plasmin.
Available antifibrinolytic agents are tranexamic acid and EACA (?-
aminocaproic acid) and apoprotin. Apoprotin antifibrinolytic agent which
acts by inhibiting serine proteases was found to be associated with high
mortality in the BART study and hence withdrawn from the market.
TRANEXAMIC ACID is a synthetic analog of the amino acid
lysine. The empirical formula is C8H15NO2 and Systematic (IUPAC)
name is trans-4H-aminomethylcyclohexanecarboxylic acid. The
molecular weight is 157.2. pKa is 4.3 and 10.6. The chemical structure is
11
Fig :1 Chemical Sructure of Tranexamic ACID
It is a white odorless crystalline powder which is freely soluble in
water, glacial acetic acid but insoluble in ethanol and acetone. Aqueous
solution for injection has a pH of 6.5-8
PHARMACODYNAMIC PROPERTIES
Antifibrinolytic property of tranexamic acid is through:
1. Reversible, competitive binding to one lysine binding sites on
plasminogen with high affinity and four other sites with low
affinity, so that it can no longer bind with plasminogen activator.
2. Non competitive blocking of ?2 antiplasmin.inhibition of
proteolytic action of plasmin by blocking the binding of ?2
antiplasmin.
3. Both tranexamic acids and EACA interact with low affinity lysine
binding site of kringle 5 domain, but when compared to EACA,
12
tranexamic acid has 6-10 times more binding potency to
plasminogen12.
4. At blood concentration <10 mg/ml the TXA has no effect on blood
coagulation parameters (i.e platelet count, prothrombin time,aPTT)
5. At concentration of 1mg/ml it does not aggregate the platelets in
vitro.However at concentration of 10 mg/ml it prolongs the
thrombin time.
The antifibrinolytic property of TXA is reflected by reduced
concentration of D-dimer , breakdown product of cross linked fibrin in
blood.
Fig:2 Coagulation Cascade & TXA
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Fig: 3 Shows Mechanism of Action of TXA
PHARMACOKINETIC PROPERTIES13
Its ideal dosage regimen for each indication is not well defined and
varied widely. It can be given through oral, parentral or topical route. The
effective therapeutic concentration of TXA for inhibiting fibrinolysis
reported by various studies is 5-10mg/l or 10-15 mg /l
? Oral administration is not interfered by food. Maximum plasma
concentration obtained at 2-3 hours .Bioavailability of oral TXA is
30-40%
? Intravenous administration of TXA with 1g dose –plasma
concentration >10mg/l will be achieved and lasts for 5-6 hours
14
? Only 3% of TXA bound to plasma proteins and is almost fully
accounted by binding with plasminogen.it is not bound to albumin
? Volume of distribution of TXA is about 0.39l/kg. Maximum tissue
distribution seen in liver,kidney,lungs.
? It diffuse rapidly into joint fluid and synovial membranes
? It can cross blood brain barrier and penetrates the eye with aqueous
humour concentration about 1/10th of plasma concentration.
? It can cross the placenta and cord blood concentration is similar to
maternal concentration.
? The concentration in breast milk is about 1% of the serum
concentration, so the excretion through breast milk is low
? 95% of drug excreted unchanged in urine.
Following IV administration of 10mg/kg , 30% recovered
unchanged in urine in one hour and 90% by 24 hours via
glomerular filtration. Overall renal clearance is equal to plasma
clearance (110-116 ml/min) 14
PHARMACOECONOMICS
The  cost  effectiveness of tranexamic  acid  has  been   studied
and  estimated  in  two  modeled  analyses.one  is  Markhov  model 15and
the other was assessing  the  use   of  TXA  over   patients in  surgical
15
bleeding  in  4   African  countries   with   HIV   prevalence   and   blood
transfusion.  Markhov model -a model over   a lifetime horizon was used
and estimated the cost effectiveness   i.e. the incremental  cost  per  life
year  gained   of   TXA  use   in  trauma   patients   with   significant
hemorrhage. The datas   were  collected  from  CRASH – 2  trial .They
compare the results  for low (Tanzania), middle (India) and  high (UK)
income  country.
Monte Carlo simulations and probabilistic sensitivity analyses were
performed. They predicted  that TXA  would  be  cost  effective  in  all
these  income countries with  incremental cost per  life year saved  of
I$48Tanzania, I$66 for India and I$64 for the UK.
METABOLISM
? Only small fraction of the drug is metabolized.
? Routes of biotransformation are acetylation or deamination
followed by oxidation or reduction.
DRUG INTERACTIONS13
? With factor IX- concomitant administration is to be avoided as
there is increased risk of thrombosis.
? With tretinoin – in acute promyelocytic leukemic patients ,
procoagulant effect of tretinoin will be exacerbated and cause
thrombotic events
16
? Not to be used along with combined hormonal contraceptives to
avoid thrombosis
? It causes cerebral vasospasm when combined with
chlorpromazine
PREPARATIONS, DOSAGE AND ADMINISTRATION14
? Oral tablets -500 mg , 15- 25mg/kg –twice /thrice daily for a period
of one week. Dose to be reduced in elderly patients due to reduced
physiological functions
? Intravenous
? Available preparations with 100mg/ml (5ml and 10ml
ampoules)
? Loading Dose -10mg/kg either direct slow IV or by infusion
after diluting with 20ml of 5%dextrose at a rate not more
than 1ml/min.
? Maintenance dose: 1mg/kg/hour IV infusion
?  oral mucosa and saliva are rich in plasminogen activator. Hence
Mouth washes containing tranexamic acid are also available and
used for hemophilia patients  before and after dental extraction.
17
DOSE ADJUSTMENT
As it is excreted through glomerular filtration, dose should be
adjusted according to creatinine clearance14,
creatinine clearance 50-80 ml/min- 50% of total dose
                                 10-50ml/min – 25% of total dose
                                 < 10 ml/min – 10% of total dose.
DRUG  STORAGE
? Tablets storage- below 30 ºc
? Injections should be stored at room temperature  in a cool, dry place
and should be kept away from heat or sunlight. Do not be freezed
INDICATIONS
As an anti fibrinolytic agent, therapeutically it can be used in all
types of bleeding as a prophylactic agent it can also be administered prior
to surgical procedures where we expect excess bleeding.
? Obstetric causes : ante partum hemorrhage, Postpartum
hemorrhaged, Caeserean section,DIC
? Gynaecological causes- AUB,conization of cervix,
myomectomy.
? Thrombasthenia related bleeding.
18
? Dental extraction and scaling in hemophilia patients.
? Orthopedic surgeries –laminectomy, knee arthroplasty, spine
fixation and total knee/hip replacement.
? Cardiac surgeries.
? Urology -Trans urethral resection of prostrate.
? Epistaxis.
? Liver transplantation surgery.
? Upper GI bleeding
? Trauma
Hereditary angioneurotic edema where it decreases the attacks by
decreasing plasmin induced complement activation.
CONTRAINDICATIONS
? Active thromboembolic diseases like DVT, pulmonary
embolism and cerebral thrombosis.
? Hypersensitivity to TXA or any of the excipients.
? Massive renal heamorrhage .
? Subarachnoid hemorrhage – since there is a risk of cerebral
edema and infarction .
? Patients with acquired defective colour vision.
19
Should be used with caution
? Patients with Drug allergy
? Renal disease patients.
? Elderly individuals with impaired renal function- dose has to
be reduced.
? Pregnancy since this is a category B drug
? Upper urinary tract bleeding-risk of clot obstruction of the
tract
? In children <2yrs of age
SIDE EFFECTS
? Commonest –gastrointestinal- Nausea, vomiting, diarrhea,
occurs in        10% cases. Dose related.
? Giddiness and hypotension – if the drug is given by sudden
rapid intravenous injection. so the recommended dose of
infusion is 50mg/min of 1%TXA administered at 5ml/min.
? Defective colour vision – in prolonged use.
? Thromboembolism – rare.
? Drug allergy – in <1% cases.
? Uncommon (>0.1% to <1%)-allergic dermatitis
20
? Gastrointestinal disturbances14 usually subside when the dose of
TXA is reduced. Giddiness and hypotension have been reported
infrequently.
? Episodes of hypotension have occurred after rapid intravenous
injection of TXA. To avoid this response, the solution should
not be injected rapidly more than 1 ml per minute.
Worldwide post-marketing surveillance data indicates
thromboembolic events (e.g. deep vein thrombosis, pulmonary embolism,
cerebral thrombosis, acute renal cortical necrosis, and central retinal
artery and vein obstruction) have been rarely reported in patients
receiving TXA for indications other than hemorrhage prevention in
patients with hemophilia (<1/1000).
There have been few reported instances of transient disturbance of
colour vision associated with the use of TXA. Patients who develop this
symptom should discontinue therapy. Hypersensitivity skin reactions
have also been reported with TXA use.13,14
DRUG OVERDOSAGE13
Tatas about over dosage are limited. One case report of drug
overdosage(37gms) reported.
21
SYMPTOMS
Headache, dizziness, nausea, vomiting, orthostatic symptoms,
hypotension.
ANTIDOTE
No antidote known. Activated charcoal can reduce the absorption
of drug if given within 1 hour of ingestion.
Cardiac and Respiratory support
            Moniter:Blood gas analysis, blood count, renal function,
electrolytes.
TRANEXEMIC ACID IN VARIOUS SURGERIES
Many surgical procedures can cause significant intra operative and
post operative blood loss. This may cause a need for blood transfusion.
Allogenic products of blood transfusion are associated with risk for
immunological reactions, HIV, TRALI, etc.
Koch et al16postulated that the perioperative red blood transfusion
is a single most reliable factor associated with increased risk of
postoperative morbid events.so its use in various surgeries limits the need
for blood transfusion thereby preventing the need for blood transfusion
related complications.
22
IN OBSTETRICS
TXA of 1g IV used in 67 subjects with abruption placenta that
reduces the perinatal mortality with no adverse effects or maternal
death.(syanberg et al)17
Tranexamic acid, 3gm intravenous infusion over 24 hours was also
used with good effect in a woman with central placenta praevia who
presented as an obstetric emergency with very heavy bleeding18
POST PARTUM HAEMORRAGE:
It is defined as blood loss>500ml for vaginal delivery, and
>1000ml for caesarean section. its has been estimated to be about 4% for
vaginal delivery and 6% for caesarean section.
Abouzahr et al (1998) postulated that PPH accounts for 1 lakh
maternal deaths per year. Many randomized nonblind and double blind
trials were conducted. In one nonblind trial (Ducloy Bouthers et al)19
conducted over 77 patients who had vaginal delivery who had PPH was
treated with 4 gms tranexamic acid and 1gm/hr for 6 hrs over infusion
when compared to similar group who have not received the drug, the
duration of bleeding was significantly shorter (p<0.01) with tranexamic
group when compared to placebo group.Bleeding has stopped
significantly in tranexamic group than control group (64% vs46%;
p<0.05).
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Gohel  M,  et  al20 evaluated the effect of  tranexamic acid in
caesarean section. They showed that tranexamic acid significantly
reduces the quantity of blood loss from placental delivery to 2 hour
postpartum, 372.71 ml in the study group versus 469.70 ml in the control
group ( P = 0.003) . It also reduces significant blood loss from the end of
LSCS to 2 hours postpartum, 75.71 ml in the study group verses 133.03
ml in the control group (P = 0.001).
SuQF, Tastsumoto K, GaiMy et al21 conducted a prospective
randomized case control trial. In this study 180 primipara were
randomized into 2 groups. In the study group, 91 women received
tranexamic acid immediately before LSCS where as in control group 89
women did not receive tranexamic  acid. The quantity of blood loss
measured in both groups. In study group from the end of CS to 2 hour
postpartum. 42.75 ±40.45 ml versus 73.98 ± 77.09 ml in control group.
IN GYNAECOLOGY
AUB- heavy menstrual bleeding is defined as a blood loss of more
than  80  ml  /day.  Normal  blood  loss  will  be  30-50  ml  /day.  Abnormal
blood loss may be due to hormonal imbalance or local uterine pathologies
like uterine fibroid ,cervical polyps Increased fibrinolytic activity seen in
women with heavy menstrual bleeding . This makes to use fibrinolytic
agent for treating the patients with AUB as an alternate due to hormonal
medications and non steroidal anti inflammatory drugs.
24
The efficacy of tranexamic acid in the treatment of heavy
menstrual bleeding has been studied in many randomized trials.
In one study by lukes et al22,a double blind randomized trial,115
patients with heavy menstrual loss was treated with 1.3g tablet
tranexamic acid three times daily for 5 days and reduction in menstrual
loss by 40%when compared to placebo group.
CONISATION OF CERVIX:
Study by Westerberg et al23,a double blind randomized trial
placebo controlled study was carried over patients who were undergoing
conization of cervix. They were treated with 1.5gm of oral tranexamic
acid 3times daily for 12 daysafter the procedure. There was significant
(p<0.05)reduction in postoperative bleeding by 70%.
MYOMECTOMY
Tasci y, caglar et al (2008)24 studied the effect of tranexamic acid
use in women undergoing myomectomy for controlling  intraoperative
and postoperative bleeding.the results showed a statiscally significant
difference between two groups when compared for postoperative
(p<0.01).
Total blood loss (p=0.03)but the perioperative blood loss(p=0.12)
and requirement for blood transfusion (p=0.25)were similar in both
groups. No adverse reactions noted.
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CARDIAC SURGERIES
Cardiac surgeries like valve replacement, coronary bypass grafting
are usually performed with cardio pulmonary bypass. This procedure
usually have excess bleeding due to derangement of coagulation system
and fibrinolysis. Many trials have been conducted.
In one randomized trial by Katsarol et al(1996)25intravenous
tranexamic 10mg/kg has significantly reduced the postoperative blood
loss  in tranexamic acid group (474 ml vs 906ml) when compared to
control group  and blood transfusion with( p<0.05-0.0001).
GASTROINTESTINAL SURGERY
Upper gastro intestinal bleeding usually results from ulceration or
erosion.six large trials have been conducted with significant good
outcome for tranexamic groups.
Hendry et al (1983)26 study with tranexamic acid for upper gastro
intestinal bleeding,there was significant reduction in bleeding in
tranexamic group compared to control group(6.3% vs 13.55;p<0.01)
Errikkson et al 27study stated that tanexamic acid is an aid for
reducing blood transfusion in gastric and duodenal bleeding.
IN TRAUMA
Globally  millions of people are dying due to road traffic accidents
and other types of trauma .In trauma patients hemorrhage is the major
26
cause of death. Hyperfibrinolysis  are frequently encountered in severely
injured patients. Every year three million people are dying as a result of
trauma.Haemostasis is responsible for integrity of circulation after severe
trauma.
Crash 2 Trial28
A large multinational randomized trial was carried out over 20211
patients.The efficacy of tranexamic acid was studied on adult trauma
patients.within 8 hrs of trauma the patients who had or at risk of heavy
bleeding were treated with1gm of intravenous  tranexamic acid as loading
dose and 1gm infused for 8 hrs or placebo.
They were followed up for 4 weeks. Tranexamic acid had
significantly reduced all cause mortality at 4 weeks. The RR of death due
to bleeding was 0.85 (95% CI 0.76,P=0.07).
ORTHOPAEDIC SURGERY
Mehr  and  Sadeghi  et  al 29 conducted a prospective randomized
double blind study, to study the efficacy of tranexamic acid versus
placebo group in patients undergoing hip fracture surgery. study was
conducted over 67patients with 32patients in tranexamic group and 35in
control group who didn’t receive the drug.
Patients in study group received tranexamic acid 15mg/kg
preoperatively prior to incision and in infusion for 3 hrs later.  The mean
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blood loss was calculated between two groups and found to be significant
reduction in tranexamic acid group when compared to control group
(950ml vs 1484ml).
The proportion of patients received blood transfusion was also
significantly less in tranexamic acid group (37%  vs 57%) and also  have
demonstrated significant (p<0.001)reductions in postoperative the mean
packed red blood cell transfusion (1.25 Vs 1.95) .No side effects were
noted in study group.
Hiippla et al30  reviewed the efficacy of tranexamic acid in
controlling preoperative blood loss and transfusion requirements of
packed red cells in patients undergoing total hip arthroplasty.
In total hip arthroplasty a pneumatic tourniquet will be applied
prior to incision to provide a blood less field. But this may enhances the
fibrinolytic system locally and thus causes increase in postoperative
blood loss usually in the first 6 hrs of postoperative period from the
release of torniniquet.study was conducted on 77 patients of which 39
patients received 15mg/kg tranexamic acid prior to incision and 6hrs
postoperatively by infusion.
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POST PARTUM HEMORRHAGE
The most common form of obstetric hemorrhage is post partum
hemorrhage. Obstetric hemorrhage is the world leading cause of maternal
mortality. It accounts for about 35% of all maternal death of which 60%
occurs in developing countries31. These deaths have a major impact on
lives and health of the families affected.
Between 1990 and 2010 there was a global reduction in maternal
death and MMR from 54300 and 400 to 28700 and 210 per 1 lakh
population. However the developing countries continue to experience
high maternal deaths when compared to developed countries32.
WHO report in 2000 stated that women in developing countries are
40 times more susceptible to die during child birth when compared to
those in developed countries. WHO 2004 – about 14 million cases of
obstetric hemorrhage occur every year.
In the developing  world , PPH is responsible for one maternal
death every 7min. in 1990, MMR in developing countries was 240/lakh
live births when compared to 16/lakh in developed countries.
 MDG5 aims at reducing the MMR by 75% by 2015. About 35
nations have been identified as either making insufficient or no progress
towards achieving MDG533. So prevention is better than cure hence
WHO recommends active management of 3rd stage  of  labour  (AMSTL)
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which can prevent PPH by 50%34 Even with AMSTL about 3 to 16.5% of
women are prone to PPH and need further management. WHO 2012
guidelines have recommended the use of tranexamic acid in all surgeries
to reduce the blood loss, as an alternative treatment of PPH when the
blood loss is partly due to trauma or other uterotonics unavailable35.
CLASSIFICATION OF PPH
Purpose to classify
? Disease progression is so rapid and so there is a need to determine
the amount of  blood loss.
? To assess the prognosis so the prognostic classification will guide
the degree of aggressiveness of intervention and management
through more than one specialty.
? To allow effective communication based on standardization of the
estimate, degree of hemorrhage and standardizing management
options.
CLASSIFICATION THROUGH VARIOUS FACTORS:
1.    Conventional Temporal Classification36
Based on timing of onset of bleed in relation to delivery
A)  PRIMARY PPH: Hemorrhage within 24 hours of delivery
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B)  SECONDARY PPH: Hemorrhage occurs after 24 hours of
delivery but within 6 weeks of delivery
2.  HEMATOCRIT CHANGE:  ACOG 200637
 Blood loss which decreases the hematocrit by more than or equal to
10%  and necessitates the blood transfusion
3.  RAPIDITY OF BLOOD LOSS38
Severe hemorrhage is
? blood loss of >150ml/min
? >50% of blood volume within 20 mins
? >2500 ml or more than or equal to 5 blood transfusion within
24hrs
4. Wac et all 2005 39
          Classified the PPH with the causative factors:
They are 4 ‘T’s:
? Tone –( noncontracting atonic uterus( 70%)
? Overdistended  uterus- Multiple
pregnancy,polyhydromnios, Prolonged  labour
? Halogenated anesthetics
? Chorioamnionitis
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? Uterine relaxants
? Grand multiparty
? Fetal Macrosomia >4kg
? Tissue - adherent placenta, retained placenta  ( 10%)
? Trauma(10%)
? Prior uterine surgery-Myomectomy,caesarean section
? Obstructed labour
? Excess cord traction
? Episiotomy /tears
? Uterine rupture
? Genital tract lacerations
? Uterine inversion
? Thrombin (coagulopathy) 1%
? Acquired
? Thrombocytopenia of pregnancy
? DIC
? IUD
? Abruptio placenta
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? Amniotic fluid embolism
? Sepsis
? Gestational hypertension
? Eclampsia
? Herediary: Von willebrands disease
? Anticoagulant therapy: Aspirin & Heparin
5.  Amount of blood lost:40
Blood loss at delivery is estimated using various methods. These
range from the less modern methods of counting blood soaked pieces of
cloth or ‘kangas’ used by traditional birth attendants in rural settings to
more modern techniques such as using a calibrated drape that is placed
under the buttocks.
Also calculating the blood loss by subtraction after  weighing all
swabs using sensitive weighing scales.
6.  Based on clinical signs and symptoms:
Bonner J et al(2000) 41
He classified the blood loss into compensatory, mild, moderate and
severe with respect to clinical signs and symptoms.
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Table: 1 Classification of Blood loss by Bonner
Types
Blood
Loss (in
ml)
TBV BP(mm Hg) Signs /symptoms
Compensatory 500- 1000 10-15% No change
Palpitations
dizziness
Mild 1000-1500 15-25%
Slight fall of
80-100mm Hg
Sweating
tachycardia
Moderate 1500-2000 25-35%
marked fall 70-
80
Pallor, oliguria
Restlessness
Severe 2000-3000 35-45%
Profound fall
50-70
Air hunger
anemia collapse
7. WHO CLASSIFICATION - all blood loss more than 500ml:
Average blood loss for vaginal delivery is 500 ml and for caesarean
section is around 1000 ml, for caesarean hysterectomy, around 1500 ml.
Any amount of blood loss more than this should be considered as PPH.
Table-2: THERAPEUTIC GOALS OF MANAGEMENT OF
MASSIVE BLOOD LOSS:
Hb >8 g/dl
Platelet count >75*10 9/L
PT <1.5* mean
Fibrinogen >1 g/L
aPTT <1.5* mean
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Blood volume restoration and that of oxygen carrying capacity of
RBC is the corner stone of resuscitation. Hence the blood loss should be
correctly estimated.
Classifications based on the need of blood transfusion and
causative factors, the ideal classification should consider both the volume
loss and the clinical consequence of it.
 Women in the developing countries like india are antenatally
complicated with anemia, undernourished and cannot even withstand
with the normal blood loss like any women in developed countries.
Henceforth in order to reduce the maternal morbidity and mortality
due to PPH ,it is essential to give good antenatal care , anemia correction
and reduce blood loss during delivery. This can be achieved with
oxytocin and antifibrinolytic drugs like tranexamic acid  to prevent
PPH .
MANAGEMENT OF PPH
The management of PPH includes:
1. Recognition
2. Communication
3. Resuscitation
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4. Monitoring
5. Investigation
6. Treatment
Reducing the caesarean section blood loss
     By the following measures
1. Preoperative measures
2. Intraoperative measures
3. Post operative measures
Preoperative measures: correcting antenatal anemia
1. Antenatal Hb% and blood grouping and Rh typing
2. Secure  IV lines
3.  Blood reservation in high risk cases
4. Coagulation abnormality if present have to be corrected before
surgery in cases of abruption placentae, IUD and HELLP
syndrome
5. Prophylactic use of antifibrinolytic drugs before surgery
6. Avoid excess and prolonged anaesthesia
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Intraoperative measures
1. Joel Cohen incision- A straight transverse incision made 3cm
above the pubic symphysis in which rectus sheath is stretched
with fingers without incising  with scissors
2. Lower segment caesarean section (avoiding classical caesarean
section)
3. Sharp method of expansion of uterine incision
4. Active management of third stage of labour(AMTSL) in
caesarean section
I. Early administration of oxytocics immediately
following the delivery of the baby
II. Controlled cord traction after placental separation
III. Uterine massage
5. Avoid undue prolongation of surgery
6. Making  J or inverted T shaped incision in obstructed labour
7. Using pattwarthans or modified pattwarthans method in cases of
obstructed labour to deliver the baby.
8. Placental bed drainage will reduce its bulkiness and allow the
uterus to contract ,thereby aids its delivery
9. Interior uterine closure for high risk cases
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MISGAV LADACH TECHNIQUE61
This technique was described  in 1994 by Dr.Michel Stark,the
presient of New European surgical academy. He was the director of
Misgav Ladach general hospital in Jerusalam.
His method was based on minimalistic principles.
Its components are
1. Modified Joel Cohen abdominal wall incision(blood vessel
injury avoided)
2. No  abdominal swab used
3. Single layer uterine closure
4. No need for peritoneal closure
5. Rectus muscle should not be approximated.
Post operative measures
1.  Intensive Post operative monitoring of high risk cases
2. Continue oxytocics in the immediate post partum period in
high risk cases
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Management of PPH during caesarean section:
A systematic and stepwise management of PPH can be achieved
with the use of the mnemonic “HAEMOSTASIS”
HAEMO –medical management
H  - ask for help
A -  Assess the vital parameters
E -  Ensure availability of blood
Establish etiology -4T’s
Ecbolics (oxytocics)
M  - Manual compression & massage the uterus
O  - oxytocin
STASIS –surgical management
S- Shift to operation theatre,bimanual compression and antishock
garments if transfer is  required(NASG-Non pneumatic anti shock
garment)
T  -  rule out tissue and trauma
A  - apply compression sutures
S  - stepwise devascularisation
I - intervention radiology (uterine artery embolisation)
S  - surgery (Subtotal hysterectomy)
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Fig  :  4 Management of Postpartum  Hemorrhage
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CESAREAN SECTION
Cesarean delivery is one of the most commonly performed
operations today.  As medical science and especially obstetrics has
evolved over the recent years, there has been a parallel and steady
increase in the rate of cesarean births.
Cesarean  section is the surgical procedure  by which baby is
delivered from the intact uterus through abdominal & uterine incision
after 28 weeks of gestation.
From times when childbirth was an event not necessitating medical
attention to the present times when concerns are voiced about high
cesarean delivery rates, obstetrics has for sure, travelled a long way.
Trends in India
India is also experiencing a rapid increase in c-section delivery
along with an increase in institutional deliveries and growing access to
gynecological and Obstetric care. The high rural urban differences in
rates invoke speculation on the possible reason for such an increase.
Reliable data on the incidence of c-section is available in India
only from the National Family Health Survey (NFHS) conducted during
1992-93. Hence, the trend of c-section deliveries analyzed from 1992-93
to 2005-06 shows an upward trend in c-section rates.
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The present analysis is based on the data derived from different rounds of
NFHS.
At the all-India level, the rate has increased from 2.9% of the
childbirth in 1992-93 to 7.1% in 1998-99 and further to 10.2% in 2005-
06. However, this scenario itself cannot be considered as a sharp increase,
nor does the figure exceed the tolerable limit speci?ed by the WHO.
In fact, the rate of increase has marginally declined if we compare
1992-93 to 1998-99 with 1998-99 to 2005-06. What has been alarming in
the case of India is the wide heterogeneity in the incidence of c-section
across states and regions. It is evident from the analysis that in 2005-06,
seven out of 19 states reported over 15% or more caesarean childbirth.
Over the last 15 years the increase in c-section delivery has been
substantial in many states. Interestingly, all the southern states recorded
c-section delivery as high as in countries with the highest level of c-
sections in the world.
The rates recorded in Kerala, Andhra Pradesh and Goa are
alarming. The data indicate that states with marked demographic
transition also record a high incidence of c-section, although the real
cause of such an increase would be different.
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SURGICAL ANATOMY FOR CESAREAN DELIVERY42
THE ABDOMINAL WALL:
Cesarean delivery is defined as the birth of the fetus through an
incision in the abdominal wall and uterine wall. Knowledge of the layered
structure of the abdominal wall permits the surgeon to enter the
abdominal cavity during cesarean delivery with maximum efficiency and
safety.
The summary of the abdominal wall layers is provided in following
box.
? Skin
? Subcutaneous layer
? Camper’s fascia
? Scarpa’s fascia
? Musculo-aponeurotic layer
? Rectus sheath
? Rectus abdominis muscle
? External/ Internal oblique muscle
? Transverse abdominal muscle  &  fascia
? Peritoneum
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Fig : 4 Abdominal Wall Muscles
As the incision for the caesarean section is made, the above layers
are  incised.
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Skin
The skin near the midline is supplied by the branches of the
superior epigastric artery (branch of the internal thoracic artery), the
inferior epigastric artery (branch of the external iliac artery) and the
superficial epigastric artery, which is a branch of the femoral artery.
The superficial arteries accompany the cutaneous nerves.  Those
that accompany the lateral cutaneous nerves are branches of the posterior
intercostals arteries, while those that travel with the  anterior cutaneous
nerves are derived from the superior and inferior epigastric vessels.
The superficial inferior epigastric vessels run a diagonal course in
the subcutaneous tissue from the femoral vessels toward the umbilicus,
beginning as a single artery which branches extensively as it nears the
umbilicus.
The skin of the flanks is supplied by branches from the intercostals,
lumbar and deep circumflex iliac arteries.  The venous blood is collected
by a network of veins that radiate from the umbilicus The network above
the umbilicus drains via the lateral thoracic vein & the axillary vein into
the superior vena cava and below the umbilicus via the superficial
epigastric & great saphenous veins into the femoral vein, and finally into
the inferior vena cava.
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A few small veins, the paraumbilical veins, connect the network
through the umbilicus and along the ligamentum teres to the portal vein.
Blood supply of the abdominal wall
The main arterial supply of the abdominal wall consists of the
superiorepigastric, musculophrenic, deep circumflex iliac and Inferior
epigastric vessels. The medial  part of the  abdominal wall receives blood
from the epigastric arteries, while the musculophrenic and deep
circumflex iliac arteries  supply the lateral wall.
The lateral wall is also supplied by the lower intercostal and
lumbar arteries (T8 toT12 and LI). This freely anastomosing vascular
system provides one continuous arterial and venous channel on both sides
of  the anterior abdominal wall,   extending  from   the subclavian vessel
cephalad to the external iliac vessels caudal. The linea alba is relatively
bloodless.
The  limited vascular supply in this area of fascial fusion can
impair wound healing when lower midline incisions are used. Thus, a
secure closure is mandatory in such incisions.The Superior epigastric
artery, one of the terminal branches of the internal thoracic artery, enters
the upper part of the rectus sheath.
The artery descends behind the rectus muscle, supplying the upper
central part of the anterior abdominal wall and anastomoses with the
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inferior epigastric artery. The inferior epigastric artery is a branch of the
external iliac artery just above the inguinal ligament. It runs upward and
medially along the medial side of the deep inguinal ring. It pierces the
fascia transversalis to enter the rectus sheath anterior to the arcuate line.
It ascends behind the rectus muscle, supplying the lower central
part of the anterior abdominal wall and anastomoses with the superior
epigastric artery. The deep circumflex iliac artery is a branch of the
external iliac artery just above the inguinal ligament.
It runs upward and laterally towards anterosuperior iliac spine and
then continues along the iliac crest. It supplies the lower lateral part of the
abdominal wall.
The lower two posterior intercostal arteries, branches of the
descending thoracic aorta and 4 lumbar arteries, branches of the
abdominal aorta, pass forward between the muscle layers and supply the
lateral part of the abdominal wall.
The epigastric vessels are subject to injury, particularly when a
muscle splitting incision is used. Also, the deep circumflex or
musculophrenic vessels can be injured when an extraperitoneal approach
is chosen.
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Fig:5 Blood Supply of Anterior Abdominal Wall
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VENOUS SYSTEM
The venous blood from the skin is connected in to a network of
veins that radiate from the umbilicus. The network drains above into the
axillary vein via the lateral thoracic vein and below into the femoral vein
via the superficial epigastric & great saphenous veins.
A few small veins, the paraumbilical veins, connect the network
through the umbilicus and along the ligamentum teres to the portal vein.
They form a clinically important portosystemic venous anastomosis.
The superior epigastric, inferior epigastric, and deep circumflex
iliac veins follow the arteries of the same name and drain into the internal
thoracic and external iliac veins. The posterior intercostal veins drains
into the azygous veins and the lumbar veins drain into the inferior vena
cava.
Blood supply of the uterus
The uterine artery is the predominant vessel supplying the uterus.
There are two uterine arteries, one arising on either side as a branch of the
anterior division of the internal iliac artery. It runs medially towards the
cervix, crosses the ureter above the lateral vaginal fornix and 2 cm lateral
to cervix, ascends upwards along the lateral uterine wall between the two
leaves of the broad ligament and then underneath the fallopian tube
anastomoses with the ovarian artery.
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The uterine vessels anastomose with each other extensively. Each
uterine artery gives rise to anterior and posterior arcuate branches along
the length of the uterus. These pass transversely into the uterine
myometrium giving off radial branches before anastomosing with their
counterpart.
The radial branches, before reaching the endometrium, supply a
basal branch to the basal zone of decidua and enter into the decidua as the
tortuous spiral arteries. There is marked spiraling of the uterine arteries
that reaches its maximum at 20 weeks.  Later, they become straight and
engorged, with the blood flow increasing from 50 ml / min to 450 - 650
ml / min.
The uterine veins, which too become engorge during pregnancy,
run along with the arteries and drain in to the internal iliac veins. The
ovarian artery arises from the abdominal aorta just below the renal artery.
It descends along the retroperitoneal space along the posterior abdominal
wall, crossing the ureter near its origin from the renal pelvis, and enters
the suspensory ligament of the ovary.
It courses underneath the fallopian tube before anastomosing with
the uterine artery.  The ovarian vein, arising from the pampiniform plexus
at the ovarian hilum  courses along with the ovarian arteries and drains
into the inferior vena cava on the right  side and in to the left renal vein
on the left side.
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The blood loss during caesarean section could be because of
inferior  epigastric  artery,  injury  or  extension  of  the  uterine  artery.    It
could also because of upper uterine segment incision or manual removal
of placenta etc. The use of tranexemic acid decreases the blood loss by
30%.  Tranexemic acid acts by inhibiting the plasminogen activator and
there by the inhibiting the fibrin degradation.
Fig: 6  Blood  Supply  and Venous Drainage to  Uterus
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BLOOD LOSS MEASUREMENT
? The Joint Commission in 201043 stated that the leading cause of
maternal morbidity and mortality is the failure to recognize
excessive blood loss that occurs during childbirth.
? The magnitude of the problem is so high .In 2009 Newyork
state department of Health44 has issued the health advisories and
informed health care providers to prevent maternal death by
improving the recognition of hemorrhage and response to it
early.
? Visual estimation of blood loss is common practice in
obstetrics. But it has its own limitation and its inaccuracy has
been demonstrated by various studies45
? Patel  et  al(  2006  )46stated that the use of visual estimation of
blood loss( EBL )can result in underestimation of blood loss by
33- 50%.
? Duthie et al (1990)47, Stafford et al (2008)48Anazi& Tamim et al
(2011)49have stated that Visual estimation consistently resulted
in underestimation of large volumes.
?  Dildy et al (2004)50 have stated that with smaller volumes, EBL
resulted in overestimation compared to direct measurement.
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Implications of Inaccurate Evaluation of Blood Loss:
? Overestimation can lead to costly, invasive, and unnecessary
treatments such as blood transfusions that expose women to
unnecessary risks.
?  Underestimation can lead to delay in delivering lifesaving
hemorrhage interventions.
? Quanti?cation of Blood Loss (QBL) is an objective method
used to evaluate excessive bleeding.
?  The quantity of blood loss estimation was started following
placental delivery. Following the uterine incision the amniotic
fluid was fully suctioned in a suction container that has
measurements in milliliter. After the placental delivery the
blood lost is suctioned in a separate suction container and
measured.
? The pads used to be weighed before and after surgery
(following placental delivery).
? 1 gram weight  =  1 milliliter blood loss volume
? AI Kadri et al ( 2011)49 stated that methods to quantify blood
loss, such as weighing, are signi?cantly more accurate than
EBL.
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? Weeber et al., Harding et al(1984)51
o Total  blood  loss  (ml)  ={  wt  of  pad  after  surgery(gm)  _
wt of pad before surgery(gm) }
+
Amount of blood  in suction container(ml)
? So Amniotic fluid and the amount of blood lost before placental
delivery was not included in measuring blood loss in our study.
? At the end of the surgery, the volume of quanti?ed blood
calculated by weight added with the volume of  quanti?ed blood
in the suction container to determine peroperative total
QBL52.To measure postoperative blood loss the pad soaked
after completion of LSCS to 2 hours postpartum were separately
weighed.
? This gives only the approximate amount of blood loss but this is
the only practically feasible method to quantify the blood
loss.So we used this method of estimation of blood loss in our
study.
? The datas were collected and analysed by using SPSS 16.0V
.Descriptive statistics - mean, median, and standard deviation
were calculated between two groups. Chi – square test (?) 2 was
used for comparison between groups regard qualitative
variables.
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? The  comparison of  quantitative  variables were calculated by
using significance of difference by independent  ‘t’ test   with
5%  level  of  significance(   ?  ).so   P   <0.05    is  considered
significant in our  study.
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MATERIALS AND METHODS
      The study was done by Dr.D. Punitha Meenakshi at
Government Chengalpattu Medical College Hospital between November
2013  to August  2014.The source of data for this study are patients who
were admitted in the Antenatal ward and Labour ward who were planned
for  elective and emergency caesarean section  at Chengalpattu medical
college hospital, Chengalpattu
Inclusion Criteria
? Primi  and  second gravida  with term  gestation
? Singleton  pregnancy
? Emergency and elective   cases for caesarean section
Exclusion Criteria
?  Allergic to tranexamic acid
? Severe  medical illness  like cardiac, Renal and Liver diseases
? Patients with past history of thromboembolic disorders
? Complicated  pregnancies at risk of   PPH
o PIH,Preeclampsia
56
o HELLP
o Anaemia with  Hb  < 9gms%
o Abnormal  placenta –Abruptio placenta,Placenta  previa
o Polyhydromnios
o Multiple pregnancy
o Estimated  fetal weight  > 4kgs ( Macrosomia )
o Myoma uterus  with pregnancy
o Prolonged  labour
o  Anesthesia-Halogenated /General anesthesia
Methods
? The  subjects of this  Randomized  Controlled  trial  were 200
patients   who were admitted  for  elective  and emergency
caesarean  section in labour ward  and antenatal  ward.
? Detailed obstetric and Medical History was taken in all patients.
Their weight and Height were recorded. Vital parameters were
checked. General, systemic and obstetric examination was done.
USG was done to confirm gestational age, fetal wellbeing,
liquor status. Complete blood count at the time of admission
and on 3 rd postoperative period was done. Bleeding Time,
57
Clotting Time at the time of admission. Renal and Liver
function test at the time of admission and on 3 rd postoperative
period. Urine was examined for Albumin, Sugar and Deposits
during admission
? Subjects were   randomized by BLOCK RANDOMIZATION.
? 100   Antenatal   women  were  placed   in  STUDY   GROUP
(Group   A  )   and   100   antenatal   women   were  placed   in
CONTROL GROUP(GROUP  B)  with the same inclusion and
exclusion  criteria.
? All patients were informed about the study and the effects of
drug  Tranexamic acid and consent  was obtained after
counseling the patients.
STUDY   GROUP
? Patient  in this  group received   injection  Tranexamic acid
15mg /kg   dose    infusion  in   100  ml   Ringer  lactate   solution
over 10 - 15 minutes  prior to the  skin incision.
? After Delivery of Baby during Cesarean Section, they received
Injection  oxytocin  10  units indramuscularly.
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CONTROL GROUP
? Patient in this group did not  receive injection Tranexamic acid.
Just   they   received plain Ringer lactate. Lower segment
caesarean section was done under spinal  anesthesia.
? After   the   delivery   of  the   baby  ,  they  received  Injection
oxytocin  10  units intramuscularly.
? Both groups received parentral Antibiotics just prior to surgery.
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Fig : 7 Injection Tranexamic acid
60
(I)  Age, (II) BMI
Age was recorded from History.
Patients Height and Weight were measured and BMI was
calculated from  the height and weight using the formula
BMI  =  Weight in kg / Height in m2
(III)  Parity
Parity was recorded from history
(IV)   Indication for Cesarean Section
The indication for Cesarean Section was recorded from Case Sheet
(V)  Duration of Cesarean Section
The Duration of Cesarean Section was recorded from beginning of
Skin incision to closure of skin.
(VI)  Birth weight of Baby
Birth weight of the baby was measured using Baby Scales.
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Pre Op and Post Op Vital Parameters:  (VII) Heart Rate (VIII)
Systolic BP (IX) Diastolic BP (X) Respiratory Rate
Both during  preoperative and  postoperative  periods  vital  signs
were measured Heart rate(HR),Blood  pressure(BP) ,Respiratory  rate
(RR)  preoperatively  and  2 hours  postpartum
(XI)  Blood Loss during and following Cesarean Section
Amount of blood loss   measured intraoperatively   from placental
separation to end of surgery. Postoperative blood loss calculated from end
of caesarean section to 2 hours postpartum. Total blood loss arrived by
the adding blood loss in both periods.
Fig :  8  Electronic  Weighing Machine
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Fig: 9  Suction Apparatus with container
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(XII)  Fall in Hb %
This is the difference between Hb % on Admission and Hb % on
3rd Post Operative Day.
(XIII) Incidence of PPH
Blood Loss > 500 ml was considered as PPH
(XIV) Need of Maternal Blood Transfusion
All mothers who had blood transfusion post operatively were
considered to be in need of Maternal Blood Transfusion. (Those who had
Pre Op Blood Transfusion were excluded from study)
(XV)  Use of Additional Uterotonics
Need for any additional uterotonics like
? 2nd Dose of  inj.Oxytocin
? Inj.Prostadin Injection
? Tab Misoprostol were noted.
(XVI)  Prolonged Hospital Stay
Prolonged Hospital Stay was defined as Stay more than or equal to
9 days. It is customary to discharge the patient on 8th Post Operative day
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(XVII)  APGAR
APGAR Score was calculated at 1 minute and again at 5 minutes
(XVIII) Admission Rate in NICU
Admission in Neonatal Intensive Care Unit for any reason was
considered
Incidence of (XIX) Nausea, (XX) Vomiting, (XXI) Diarrhea,
(XXII) Thrombosis
Incidence of the above four conditions were measured in both the
study group and control group
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OBSERVATIONS AND RESULTS
The overall results of this study are as shown below
(I)  Age, (II) BMI
The mean Age in Study Group was 24.05 and the Mean Age in
Control Group was 24.47 with. The SD in Study Group was 2.641 and the
SD in Control Group was 2.68
The mean weight in Study Group was 56.85 kgs and the Mean
weight in Control Group was 57 kgs. The SD in Study Group was 5.776
and the SD in Control Group was 6.184
The mean height in Study Group was 155.5 cm and the Mean
height in Control Group was 153.84. The SD in Study Group was 4.356
and the SD in Control Group was 7.738. The mean BMI in Study Group
was 22.931 and the Mean BMI in Control Group was 23.517
The SD in Study Group was 1.7342 and the SD in Control Group
was 2.3474.
 ‘t’ values and p values were calculated. It was found that
confounding variables such as Age, Weight, Height and Body Mass Index
(BMI) are matched effectively in both study and control groups.
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The differences in confounding variables (Age, Weight, Height,
and BMI) in both groups were not statistically significant.
Table: 3 Comparison Of Age BMI
Character
Study Group Control Group
‘t’ value P value
Mean SD Mean SD
Age 24.05 2.641 24.47 2.68 1.116 0.27(NS)
Weight 56.85 5.776 57 6.184 0.177 0.86(NS)
Height 155.5 4.366 153.84 7.738 2.01 0.05(NS)
BMI 22.931 1.7342 23.517 2.3474 2.01 0.05(NS)
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 (III) Parity
The following table   shows   the comparison of parity between two
groups. 72 patients   in Study Group and 65 patients   in   control   group
were   Primi   gravidas. 28   patients   in   Study Group and 35 patients in
Control  Group  were  second    gravida.  P  value  is  0.181  which  is    not
statistically   significant. Parity was comparable in both groups.
Table :4 Comparison Of Parity
Parity Study Control
Chi  square
test
P   value
Primigravida 72 65
1.135
0.181
(Not
significant)
Second
Gravida
28 35
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(IV)  Indication for Cesarean Section
The indications for Cesarean section can have bearing on amount
of intra operative and postoperative blood loss. Indication for Cesarean
Section between two groups are shown in the following table were
compared.
Table :5 Comparison of indication for caesarean section
Indication for Cesarean Section Study Group Control Group
CPD 24 20
Fetal Distress 41 49
Oligohydramnios 15 9
Malpresentation 16 10
Failed Induction 3 4
Previous LSCS with PROM 1 6
Precious Baby 0 2
P= 0.14 (Not  significant) Chi  square test
It is found that in this study, there is no  statistical significance  in
indication  for  LSCS  in  both  Study Group  and  control   group. Hence
This does not act as a confounding variable in this study.
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(V)  Duration of Cesarean Section
Operating time can affect the amount of blood loss and hence they
were studied
Table :6 Comparison of duration of caesarean section
Variables
Study Group ControlGroup ‘t’
value P value
Mean SD Mean SD
Duration of
Cesarean
Section
43.12 2.337 42.61 2.562 1.47 0.10(NS)
The mean duration of surgery in study group was 43.12 minutes
and in Control Group was 42.61 minutes (P=0.10).The difference in
duration of surgery in both groups was not statistically significant.
Hence we found that Operating time is not a confounding variable
in our study.
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(VI)  Birth weight of Baby
Comparison  of  (VI)  Birth  weight  of  Baby  between  study    and
control   groups revealed that the mean baby weight in Study Group was
3.2382 kg and in Control Group 2.9875kg (P-0.03) and that there is no
statistical difference in birth weight of baby in both the groups.
Table :7  Comparison of Birth Weight of Baby
Variables
Study Group ControlGroup ‘t’
value P value
Mean SD Mean SD
Birth weight of
Baby
3.2382 2.52961 2.9875 0.4253 0.977 0.33(NS)
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2.9875
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Pre Op and Post Op Vital Parameters: (VII) Heart Rate(VIII)
Systolic BP (IX ) Diastolic BP (X) Respiratory Rate
There was no statistically significant difference in the vital signs
before and 2 hours after delivery in both the groups.
Table : 8 Comparison of Preop and Post Op Vital Parameters
Parameters
Study Group ControlGroup ‘t’
value
P
value
Mean SD Mean SD
Pre Op Systolic BP 116.82 7.37 116.12 8.389 0.627 0.53
Post Op Systolic BP 115.24 6.933 114.26 9.006 0.862 0.39
Pre Op Diastolic BP 77.58 4.238 78.26 5.747 0.95 0.3
Post Op Diastolic
BP 74.82 4.654 84.6 78.545 1.243 0.22
Pre Op Heart rate
Rate 83.78 9.644 82.44 4.854 1.241 0.22
Post Op Heart Rate 83.87 8.442 82.7 5 1.192 0.24
Pre Op Respiratory
Rate 16.89 0.777 17.01 0.759 1.105 0.27
Post Op Respiratory
Rate 16.97 0.703 17.14 0.682 1.736 0.08
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(XI)  Blood Loss during and following Cesarean Section
The following Table shows the Blood Loss. Mean blood loss from
time of placental delivery to  completion of skin closure was 266.4 ml in
the  Study  Group  and  it  was  380.8  ml  in   the  Control  Group  (P=  0.00),
suggesting that there was statistically highly  significant difference in
blood loss in both the groups.
Patients who had received tranexamic acid had 114.4 ml less blood
loss than patients who did not receive tranexamic acid.
Mean  blood  loss  from  time  of  completion  of  skin   closure  to  2
hours postpartum was 40.93 ml in the Study Group and it was 73.7 ml in
the Control Group (P= 0.00), suggesting that there was statistically highly
significant difference in blood loss in both the groups.
Patients who received tranexamic acid had 32.77 ml less blood loss
than patients who did not receive tranexamic acid.
Mean  total  blood  loss  from  placental  delivery  to  2  hours
postpartum was 307.33 ml in the Study Group and it was 454.5 ml in the
Control Group (p=0.00) suggesting that there was statistically highly
significant difference in blood loss in both the groups.
 Patients who received tranexamic acid had 147.17 ml less blood
loss than patients who did not receive tranexamic acid.
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Hence from the above result it is obvious that tranexamic acid is a
potent antifibrinolytic drug that influences the blood loss in cesaerean
section and its therapeutic efficacy can be used in minimizing caesarean
section blood loss.
Table : 9 Comparison of Blood Loss
Blood Loss
Study Group Control Group ‘t’
value
P
valueMean SD Mean SD
Placental delivery
to  completion of
skin closure
266.4 54.46 380.8 75.62 12.275 0.00
Time of completion
of skin  closure to 2
hours postpartum
40.93 8.3 73.7 16.81 17.47 0.00
Total Blood Loss 307.33 58.86 454.5 82.74 14.49 0.00
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(XII) Fall in Hb %
Preoperative Hb% was compared to Hb% in 3rd postoperative day
in both study and control group. There was a fall of 0.74gm% in study
group while the fall in control group was much higher at 1.02 gm%.  The
mean difference is 0.28 gm% which is highly significant (P=0.001)
Table : 10 Comparison of Fall In HB
Hb%(gms%)
Study Group
(1)
Control Group
(2) ‘t’
value P value
Mean SD Mean SD
Pre operative 10.358 0.596 10.6 0.6
5.183 0.001(S)Postoperative 9.61 0.516 9.63 0.778
Fall in
hemoglobin
0.74 0.3288 1.02 0.384
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(XIII) Incidence of PPH
The following Table   shows the comparison of incidence of PPH
(defined as loss > 500ml)   in both groups. We find that in study group 1
patient    had    a  PPH.  In    Control  Group  7  patients  had    PPH.
Statistically this is significant as per Chi Square test, but not significant as
per Yates Correction.
Table :11 Incidence Of PPH
PPH : Blood
loss >500 ml
Study
Group
Control
Group
Chi  square
TEST
P
VALUE
Present 1 7
3.26 0.07(NS)Absent 99 93
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(XIV) Need of Maternal Blood Transfusion
Table :12 Comparison Of Need For Maternal Transfusion
Maternal  blood
transfusion
Study
Group
Control
Group
Chi
square test
P  value
Needed 1 5
2.75 0.11(NS)
Not needed 99 95
Table shows the need of maternal blood transfusion in both groups.
In  TXA  group 1  patient  had  a blood  transfusion  whereas   in  Control
Group  5  patients  had  blood  transfusion .The   difference was   found
to  be not statistically  significant.( p=0.11)
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(XV) Use of Additional Uterotonics
Table :13 Comparison of Need of Additional Uterotonics
Use of Additional
Uterotonics
Study
Group
Control
Group
Chi
square P value
Needed 3 8
2.4 0.11(NS)
Not Needed 97 92
Table  shows   the   need for   additional  uterotonics   between  two
groups. In  TXA   group 3  patients  needed  additional  uterotonics but  in
control   group  8  patients  needed  additional  uterotonics.But there
found to be no  statistical   significance (p=0.11)
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(XVI) Prolonged Hospital Stay
Table :14 Comparison of Prolonged Hospital Stay
Prolonged
Hospital   Stay
>9 days
Study
Group
Control
Group Chi  square test P  value
Needed 1 4
1.84
0.18
( NS)Not  needed 99 96
Table  shows   comparison   of    hospital   stay    between   study  (
TXA  ) group  and   control   group. 1  patient  in     study   group  and   4
patients   in    control    group    had    prolonged    stay.  There   is   no
statistical    significance   between  two    groups .(  p=0.18 )
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 (XVII) APGAR
Comparison  of  (XVII) Apgar  between  study and  control  groups
at   1   and   5  minutes showed Study Group had mean Apgar score of
7.02 at 1min & 8.02 at 5 min, while newborns born to subjects in Control
Group had mean Apgar score of  7.01 at 1 min &7.6 at 5 min. There was
no statistically significant difference in Apgar score in both the groups.
(Mean and Median are same at 1 min & at 5 min in both groups).
Table: 15 Comparison of Apgar at 1 and 5 minutes
APGAR
Score
Study Group Control Group
Mean Median Mean Median
At 1 Minutes 7.02 7 7.01 7
At 5 Minutes 8.02 8 7.6 8
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(XVIII) Admission Rate in NICU
Table:16 Comparison of Admission In NICU
Admission in
NICU
Study
Group
Control
Group
Chi
square test
P  value
Needed 3 4
0.15
0.5
(Not
significant  )
Not  needed 97 96
Table   shows need   for   NICU    admission in   both   groups.  3
babies  in  study   group   and  4   babies in  control   group admitted in
NICU but  has  no  statistically significant   difference  in  both   groups.
Thus, tranexamic acid has no significant difference in relation to fetal
outcome.
91
Incidence of (XIX) Nausea, (XX) Vomiting, (XXI) Diarrhea, (XXII)
Thrombosis
Table :17 comparison  of   incidence of vomiting, nausea, diarrhoea,
thrombosis
Complications Study Group Control Group
Nausea 5 3
Diarrhoea 1 0
Vomiting 5 4
Thrombosis 0 0
Total 11 7
Table  shows  that   5   patients  in  study   group  and   3 patients
in Control Group  had nausea.5  patients  in  Study Group  and  4  in
control  group  had   vomiting.1 patient  in  study   group  and  none  in
control   group had  vomiting. None of  the patients in  study  and  control
group  had  thrombosis.
The   incidence of   drug   side   effects  like  Nausea, vomiting ,
diarrhoea  were  not  increased  in  study  group  as  compared  to  control
group.  Thus   suggesting   that  the   use  of   Tranexamic   acid   had   no
significant  adverse  reactions.Also there  was no incidence of
thrombosis  in TXA  group.
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ANALYSIS  AND DISCUSSION
(I)  AGE, (II) BMI:
In  our  study  patients in both  Study Group  and  control  group
were  matched with no  significant  difference.
Similar  to  Amr  H .Yehia et al53study in which the two studied
groups were matched with no significant difference between the study
and control groups regarding the  variables mean age, body mass index
(BMI)  and  gestational  age.  In  this   study   the  mean age  in  TXA  group
was  (28.4±4.9  vs  28.6±4.7) in placebo group. Mean BMI  was (22±1.6
vs  27.5±2.0)  in TXA  Vs  placebo  group   respectively.
Other  studies  like  Ayesha  et  al54  the two  study  groups were
matched  with  no significant  difference in  Age,  BMI  and  Gestational
age. In this  study  the  mean age in TXA  group  vs  control  group was
24.18±3.93  vs  24.89 ±4.16 with( p=0.45).
(III)  PARITY
In this study Primi  and  second  gravida  with   full term singleton
pregnancy delivered by  elective / emergency  LSCS  were  included  in
our   study  subjects   with  medical   problems  and  with  increased  risk  of
developing  PPH  were    excluded  in  this   study    which  is   similar  to  a
study  conducted at  Karachi in  2013 by Ayesha et al.
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Other similar studies comparable were Mayur et al55(2004), ayesha
et al (2009-11)  H Yehia et a(l2014)
(IV)   Indication for Cesarean Section
It can have a bearing on amount of blood loss. They were matched
adequately in both groups and thus removed the effects of   these
confounding variables in our study. Similar to this study was conducted
by Mayur et al with no statistical significance difference in indication for
LSCS.
(V)  Duration of Cesarean Section
The  duration  of  surgery  can  alter the amount  of blood  loss and
vital parameters In this study the duration study in study & control group
were   (  43.12±2.337   Vs  42.61±2.562  min  respectively   with   P   value
0.10  (NS).This  is   comparable   to   other   studies   like  Ayesha   et   al
where  the  mean duration  of  LSCS  was  47.5 min.
Mayur et al study, the difference in the duration of surgery between
two  Groups were not statistically significant (47.75 min Vs 48.57min in
study & control group respectively).These  results  were comparable to
our study.
(VI)  Birth weight of Baby
The mean baby weight   in our study was found to be 3.2382 ±
2.52Vs 2.987±0.42 with p=0.33  in study  group and control  respectively.
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The difference was statistically not significant. Similar results were found
in Mayur et al study, there was no difference in mean weight birth weight
between two groups.
Pre Op and Post Op Vital Parameters : (VII) Heart Rate (VIII)
Systolic BP (IX ) Diastolic BP (X) Respiratory Rate
In our study there was no statistically significant difference in heart
rate, systolic and diastolic blood pressure, respiratory rate between two
groups.  These  results  were  similar  to  study  conducted  by  Mayur  et  al,
Ayesha et al and Amr H.yehia et al.
(XI)  Blood Loss during and following Cesarean Section
Our study showed that Tranexamic acid has significantly reduces
the bleeding during both the periods that is from the time of placental
delivery during caesarean section to end of skin closure(266.4±54.46 V
s380.8±75.62) and from end of skin closure to 2 hours postpartum
period(40.93±8.3Vs73.7±16.81).Results showed that the mean total blood
loss in study group who received tranexamic acid was 307.33ml±58.86 as
standard deviation, while in control group patients had mean loss of
454.50ml ±82.74 as standard deviation. Thus there was a reduction is
blood loss by about 147.17ml and was found to be statistically highly
significant (p=0.001).
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Similar study was conducted by Cemal ark, Gokhan,Gungorok56
and coworkers. They performed a randomized, double-blind, placebo-
controlled study of 660 women who underwent elective CS. The patients
were randomly selected to receive an intravenous infusion of either TXA
(1 g/10mL  in  20  ml of  5%  glucose; n=330)  or  30  ml 5%  glucose
prior   to   surgery.   The  primary  outcome  was  the  estimated  blood  loss
following CS. No demographic difference was observed between
groups.The   mean  estimated  blood  loss   was  signi?cantly  lower   in
women  treated   with   TXA  compared   with   women  in   the   placebo
group(499.9±206.4 ml versus 600.7±215.7 ml respectively; p<0.001).
Sekhavat et.al (2009)58 conducted a prospective randomized trial
on 90 primiparas who underwent CS and grouped them in 2 groups. In
study group there were 45 women, received tranexamic acid immediately
before CS, whereas the control group, 45 women received placebo. Blood
loss  volume was  measured  from the  end  of  CS to  2  hrs  postpartum and
compared between the two groups. Their results showed that tranexamic
acid significantly reduced the blood loss from the end of CS to 2 hrs
postpartum; 28.02 ± 5.53 ml in the tranexamic group versus 37.12 ± 8.97
ml in the control group (p = 0.001).
Amr H .Yehia  et  al  (2014)calculated blood loss from placental
delivery till end of surgery in  study &control group (369.5±198.0 versus
606.8±193.0 ml, respectively), also calculated vaginal bleeding during
first 6 hours post-operative  period was significantly less in study group
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compared to control (85.0 ±30.7 versus 130.8 ±49.3 ml,  respectively),
and calculated total blood loss from placental delivery till 6 hours post-
operative was significantly less in study group compared to control
(454.5± 201.0 versus 737.6 ±217.0 ml, respectively).
Also few other studies like  Gaimy  et al57,Gohel  et al ,Gungorduk
and  colleagues study ,xu  et al also shown  similar results like our  study.
But one study by Ayesha et al  should there was  significant reduction in
preoperative blood loss in TXA  group than  placebo group
(356.44±143.2ml Vs 710.22ml ±216.72ml) with p<0.001.it reduced the 2
hrs  postpartum  blood loss but not to significant level (35.68±23.39 l
versus 43.63± 28.04) (p=0.188).
(XII) Fall in Hb %
In our  there was significant fall of postoperative Hb%  level  in
control  group  when  compared to  study  group (1.02  Vs  0.74  with “t “
test value of  5.183 with  significant   p  value=0.001
Abdelazim  et al (2014) There was no significant difference
regarding pre-operative hemoglobin value was found, but the 24 hours
post-operative hemoglobin was significantly higher in study group (11.2±
1.5 mg/dl) compared to control group (9.6 ± 1.2 mg/dl ( P<0.05 )
Similar  reports were seen in  a study by sekavat et al – Hb% 24 h
after CS was significantly greater in tranexamic group than control group
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(12.57 ± 1.33 in the tranexamic group and 11.74 ± 1.14 in the control
group, p= 0.002). No complications or side effects were reported in either
group.  Other  studies  like  Mayur   et  al  ,Ayesha   et  al   also   had   similar
results  like our study
(XIII)  Incidence of PPH
Tranexamic acid also found to decrease the incidence of PPH i.e.
the blood loss more than 500ml in the study group when compared
control group. In this study only 1 patient had PPH and in control group 5
patient had PPH with P= 0. 07 but without statistical significance.
Yang HX, et al59showed similar results. Tranexamic acid
significantly reduced postpartum blood loss after vaginal delivery. The
occurrence of postpartum hemorrhage was 6.4% in study group as
compared to 25.3% in control group, which was statistically significant.
There were no significant adverse effects. Therefore, tranexamic acid is
efficient & safe in reducing postpartum hemorrhage.
In Ayesha et al study also similar result were seen. This study also
showed reduction in the incidence of postpartum hemorrhage to 13%
from 30% in TXA group as compared to placebo. Amr H.Yehia  et al also
showed  in  their study that  the  incidence  of  PPH   was  significantly
less  in  study   group  who   received  TXA   when   compared  to   control
group( 31.1% versus 63.2%  respectively)
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(XIV)  Need of Maternal Blood Transfusion
In this study only one patient  in Study Group  had blood
transfusion. In control group 5 patients had blood transfusion. But
without statistical significance.
In Ayesha et al   study also similar results were seen , study on 74
full term pregnant women delivered by  LSCS, where 12 patients from
the placebo group required the blood transfusions while 3 patients in the
Study Group required transfusion.
In  Amr H.Yehia  et al  study no  blood transfusion  was  needed in
study  group while  two  in control group had  blood  transfusion but the
difference was not statistically significant. These  results  were similar to
our  study.
(XV)  Use of Additional Uterotonics
In our study additional uterotonics  were needed more in control
group than  study  group.  only 3 in study group were received  additional
uterotonics  when compared  to control group where  8  patients  received
additional  uterotonics.
Cemal ark eta al:Study  on  660 women undergoing   elective
caesarean  section  found  that  the  proportion   of   women   in   the   TXA
group   with  PPH  was  signi?cantly  lower  than  in  the  placebo  group  (7
[2.1%] versus 19 [5.8%], respectively, with relative risk [RR] 2.7; 95%
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con?dence interval [CI] 1.1 to 6.3; p<0.03). Furthermore, more women in
the placebo group than in the Study Group required additional uterotonic
agents (48 [14.5%] versus 28 [8.5%], respectively; RR 1.7; 95% CI 1.1 to
2.6; p=0.02).these results were similar to our  study.
(XVI)  Prolonged Hospital Stay
In our study one mother in study  group and  4  mothers in
controlled group had prolonged hospital stay but without statistically
significant difference(p=0.18). One mother in study group had prolonged
stay  as  the  baby  had  low  birth  weight  and  HMD  had  NICU  care.  She
discharged on 11 th POD.
4 mothers in  control group had prolonged  hospital stay ,among
them  one had breast  engorgement  and  fever and another one for  baby
sake as two babies were  low  birth  weight and  neonatal jaundice and
were  admitted  in  NICU  care  ,one  had   wound  infection  and  fever  and
treated with appropriate antibiotics after  pus  culture  sensitivity.
Similar to this result in Gurunanak et al  the prolonged hospital
stay was statistically significant in both  study and  control   groups
(2.0±0.1  Vs 2.0±0.0)respectively with P=0.10 (NS)
(XVII) APGAR
In our study 1 and 5 minutes mean Apgar score were found to be
7.02&8.02 Vs 7.01 &8.67 with  no statistically significant  difference.
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Similar  results were seen in Mayur et al study where they found that
Tranexamic acid had no significant effect on 1 & 5 minutes Apgar score
between two groups with(P=0.5). Others studies like Ayesha et al,Amr
H.yehia et al also showed similar results as in our study.
(XVIII)  Admission Rate in NICU
In our  study ,the neonatal outcome were comparable in both  study
and  control   groups.3  babies  had  NICU  admission.  one   admitted  for
neonatal jaundice and the indication for LSCS was   severe
oligohydromnios and  had  phototherapy and discharged  on  3th POD.
Another   baby  was   low  birth   weight  and   HMD.  The  indication  for
caesarean section was severe oligohydromnios and discharged on 10th
POD.
Another had  TTN and the indication for LSCS was fetal distress.
Baby was admitted in NICU and discharged on 4th POD. In  control
group 4  babies were admitted in NICU. Among them  one had  HIE and
the indication for LSCS  was fetal distress. Treated and discharged on 5th
POD.2 Babies were low birth weight and the indications for LSCS were
PL/PROM and the other for flexed breech. Both  were discharged in good
health on 11th POD. Another baby had neonatal jaundice, admitted in
NICU and discharged in good condition on 4th POD.
This  shows that TXA was not associated with any impact on
neonatal outcome in our study. similar  results were seen in a study
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conducted by Abdelazim  ,Amr H.Yehia and  coworkers at  in
Department of  Obstetrics & Gynaecology, Ain  Shams  university ,Cairo
,Karachi, there was no adverse neonatal outcome in their study.
Incidence of (XIX) Nausea, (XX) Vomiting, (XXI) Diarrhea, (XXII)
Thrombosis
In  this   study,   the  incidence  of  the   drug   side   effects  like
Nausea,vomiting,diarhhoea   were not statistically significant increase  in
study group when  compared to  control  group.
Out of the 5 patients in the study group one patient recieved
additional uterotonics like 2nd dose inj.prostadin(PG F2 ?)& inj. oxytocin,
Tab. Misoprostol and 4 did not receive any other drugs. Similarly out of 4
patients with vomiting in the control group only one patient received
additional uterotonics for PPH and 3 did not.
Excluding the administration of additional  uterotonics as a cause
of vomiting,the incidence of vomiting otherwise is almost similar in both
groups without any statistically significant difference. All the patients
received parentral antibiotics  just prior to surgery & the emetogenic
effect of antibiotics in causing vomiting was considered and same in both
groups.
 Pregnancy  is  an  hypercoagulable  state and the incidence of
thrombosis during pregnancy and puerperium is 5-6 times higher than
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that in the general population.So when the anti fibrinolytic drug
tranexamic acid is administered, the increased risk of thrombosis should
be considered, especially in the LSCS postpartum population. In our
study, not a single patient developed thrombotic  events.
Senturk & colleagues Study Group didn’t observe any
complications caused by TXA such as venous thromboembolism,
gastrointestinal problems and hypersensitivity .
Also, Mayur et al, concluded in their study that not  even  a single
patient in Study Group developed thrombosis and the  incidence of  side
effects like  nausea,vomiting and diarrhoea were found to be not
statistically significant by  difference in both groups. These results were
corroborated by Yang  H et al,  Lindoff C et al60, Gai MY  et al.
Limitations of our Study
There are few limitations in our study
? Blood Loss from Skin Incision till delivery of Placenta is not
included in our study
? High Risk Population for PPH was is not included in this study
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CONCLUSION
? There is no significant difference in Age, BMI, Parity, Indication
and Duration of Cesarean Section and Birth weight of Baby
between the study group and control group. Both Groups are
comparable.
? Intravenous infusion of Tranexemic Acid at the dose of 15 mg/Kg
Body Weight, initiated 15 minutes prior to Skin Incision
o does not alter the (1) Heart rate, (2) Systolic BP, (3)
Diastolic BP and (4) Respiratory Rate
o leads to significant reduction (p <0.05) in Per Operative
(average 114.40 ml) and Post Operative Blood Loss (average
32.77 ml) during Cesarean Section. Total Blood Loss is
reduced by an average of 147 ml.
o leads to significant (p <0.05) difference in fall of Hb level in
control group who have not received inj.Tranexamic acid.
The mean difference was 0.28gms%(P=0.01)
o leads to Reduction in (1) the incidence of PPH, (2) need for
maternal blood Transfusion, (3) Use of additional
Uterotonics, (4) Duration of stay in an insignificant manner
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o does not alter the APGAR Score and Rate of admission into
NICU, in a significant manner.
o does not produce other adverse reactions like nausea,
vomiting, diarrhea in a significant manner. It was not
associated with thrombotic complications.
? Intravenous infusion of Tranexemic Acid at the dose of 15 mg/Kg
Body Weight, initiated 15 minutes prior to Skin Incision is
effective and safe in women undergoing caesarean section in
reducing preoperative and postoperative cesarean section blood
loss .
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APPENDIX III
 COPY OF PATIENT INFORMATION SHEET
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APPENDIX IV
 COPY OF PROFORMA USED
PROFORMA
Name  :                                                                       Booked/UnBooked  :
Age:
 I P No    :
Occupation :                                                     D O A     :
                                                                          DOS       :
Address :                                                           D O D    :
Type of surgery: Elective//Emerg
Condition of patient at discharge     :
Diagnosis  :
PRESENTING COMPLAINTS
 Period  of Amenorrhea :
 Labour Pains :  Yes/No
 Draining  Pervagina : Yes/No
 Bleeding Pervagina : Yes/No
 Perceiving Fetal Movements : Yes/No
 Antenatal checkup :  Regular/Irregular
 Immunized with inj. TT : Yes/Not
 History Suggestive of UTI  :
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OBSTETRIC HISTORY
History of Consanguineous Marriage :   Yes/No
 Gravida :             Para:            Living :         Abortion :
HISTORY OF PREVIOUS PREGNANCIES
 MENSTRUAL HISTORY  :
 Age at Menarche :
 Previous Menstrual  Cycle   :
 Last Menstrual Period :
 Expected date of Delivery  :
MEDICAL HISTORY
Diabetes/ GDM  : Yes/No                Hypertension/  GHT : Yes/No
 Tuberculosis :Yes/No Rheumatic Heart Disease :Yes/No
 Thyroid disorder:Yes/No Bronchial Asthma             : Yes/No
PAST HISTORY
Postpartum Hemorrage : Yes/No
 Blood Transfusion : Yes/No
 Eclampsia : Yes/No
FAMILY HISTORY
Diabetes: Yes/No Hypertension  : Yes/No
Twin Pregnancy : Yes/No Tuberculosis  : Yes/No
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PERSONAL HISTORY
GENERAL PHYSICAL EXAMINATION
Built  :    Nourishment :
Pallor  :         Cyanosis :           Icterus:       Oedema :
Pulse  : Lymphadenopathy :
 BP  :                                    Breast :
                                              Thyroid :
SYSTEMATIC EXAMINATION
CVS  :
RS     :
CNS  :
Abdominal  examination - Height of the Uterus :
                                               Acting/Relaxed       :
                                               Lie :
                                                Presentation        :
                                                 Position :
                                               Fetal Heart Sound  :
 Vaginal  examination :
Cervix - Length :
                Dilatation   :
                Consistency  :
125
Position   :
OS :
Membranes :
Vertex - Station :
Pelvis :  Adequate/Inadequate
Show :  Present/ Not
Liquor  draining :  Yes /No
Clear/meconium  stained
INVESTIGATIONS
Urine    -  Albumin :  Blood groping &typing
Sugar HIV      :
          Deposits                         VDRL   :
Complete Blood Count:            HbsAg :
                  - Hb  gms%  -Day of Admission ,3 rd POD
                  - Total  count
                  - Differential  count
                  -  Hcrt
                  - Platelet count
Bleeding  Time: Clotting  Time :
RFT: LFT :
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U.S.G  Obstetrics :
 Presentation -
 liquor   status -
Placental -  Site
-  Maturity
Fetal heart sound -
Fetal  Anomalies   -
Estimated foetal weight  -
Average Gestational age
Scan EDD :
Diagnosis :
Any induction : Yes / No
 Indication for caesarean section :
Time of giving   Inj.Tranexamic acid:
Time of incision :
On  table  findings  :    Single  /  Live  /  Term    _________  Baby  weight
______ kg at time __________
Placental weight  : ____________  Liquor : __________________
Any on table or postoperative complications :
After delivery of placenta  :
Dry  Pad weight  (A) _________  After soakage weight (B) ___________
127
Blood  in suction container  in  ml  (C)  :
Total blood loss :  (B) – (A)  +  C  = _________
Preop Hb% ______________
3 rd  POD  Hb%_______________
Vitals  2 hours after CS : Systolic  BP:
                                             Diastolic BP:
                                              HR :
                                              RR :
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APPENDIX V
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1 A1 23 47603 PRIMI 62 158 25 CPD 11.14PM 11.26PM 300 46 346 40 3 7,8 110 120 70 70 88 86 18 17 11 10 0.6 _ _ _ _ _ _
2 A2 23 47614 PRIMI 58 160 23 FD 11.24PM 11.28PM 260 40 300 42 3 7,8 120 110 80 80 86 83 16 17 10 10 0.8 _ _ _ _ _ _
3 A3 27 47794 PRIMI 58 154 25 FD 11.32PM 11.44PM 310 50 360 40 4 8,9 110 110 80 70 90 92 18 18 11 11 0.4 __ _ _ _ _ _
4 A4 26 47474 PRIMI 54 151 24 Oligo 5.35PM 5.48PM 290 40 330 42 3 8,9 120 110 70 70 88 86 17 17 12 10 1.2 _ _ _ _ _ _
5 A5 20 48121 PRIMI 59 155 25 CPD 4.40AM 4.53AM 250 45 295 43 3 8,9 130 120 80 80 82 84 16 16 11 10 1.2 _ _ _ _ _ _
6 A6 28 48189 PRIMI 61 160 24 CPD 5.12AM 5.37AM 285 44 329 41 3 7,8 120 110 80 80 88 86 17 17 10 10 0.4 _ _ _ _ _ _
7 A7 24 48357 G2P1L1 58 153 25 CPD 12.50AM 1.03AM 750 70 820 43 3 7,8 100 110 80 70 84 90 16 18 11 9 2 Y Y PPH V  _  _
8 A8 22 48657 PRIMI 56 153 24 FD 5.27AM 5.41AM 280 42 322 45 2 8,9 120 120 78 76 82 80 16 16 11 10 0.4 _ _ _ _ _ _
9 A9 25 49374 G2P1L0 60 163 23 CPD 5.50PM 6.02PM 290 44 334 43 4 7,8 120 110 70 70 86 86 17 17 10 10 0.4 _ _ _ _ _ _
10 A10 28 50209 PRIMI 58 156 24 Oligo 10.10AM 10.22AM 250 40 290 47 4 8,9 110 110 80 70 84 82 17 17 10 9 0.2 _ _ _ _ _ _
11 A11 22 57069 PRIMI 61 158 24 FD 4.53PM 5.07PM 280 36 316 46 3 7,8 110 120 70 70 84 82 18 18 10 9 0.8 _ _ _ _ _ _
12 A12 21 50924 PRIMI 58 153 25 FD 5.20PM 5.33PM 240 40 280 42 3 8,9 120 120 80 70 86 84 17 18 10 10 0.4 _ _ _ _ _ _
13 A13 25 57118 PRIMI 57 151 25 Oligo 5.25PM 5.38PM 250 45 295 40 2 7,8 110 110 70 70 86 88 17 17 10 10 0.6 _ _ _ V Y _
14 A14 22 48867 PRIMI 58 152 25 Breech 9.34AM 9.50AM 240 50 290 43 3 8,9 120 110 70 80 88 84 16 17 11 10 0.4 _ _ _ _ _ _
15 A15 22 49917 PRIMI 57 160 22 FD 12.14PM 12.27PM 250 45 295 40 3 7,8 100 110 80 70 84 84 17 16 10 10 0.3 _ _ _ _ _ _
16 A16 23 49303 PRIMI 52 151 23 Breech 9.46AM 10.02AM 250 40 290 44 3 8,9 110 110 70 70 86 88 16 17 11 11 0.8 _ _ _ _ _ _
17 A17 26 49815 G2P1L1 62 159 25 CPD 9.53AM 10.08AM 280 45 325 48 3 7,8 120 130 70 76 78 80 17 16 11 10 1 _ _ _  N  _  _
18 A18 20 51235 PRIMI 54 150 24 Breech 6.40PM 6.53PM 250 35 285 44 3 7,8 130 120 80 76 90 88 17 18 10 9 0.4 _ _ _ _ _ _
19 A19 24 51846 PRIMI 59 154 25 CPD 7,17PM 7.26PM 260 32 292 42 3 8,9 110 120 70 80 82 78 18 18 10 9 0.5 _ _ _ _ _ _
20 A20 23 52291 PRIMI 52 154 22 Oligo 5.22PM 5.27PM 255 36 291 45 3 7,8 126 110 76 78 80 76 17 17 10 9 0.6 _ _ _ _ _ _
21 A21 22 52841 G2P1L1 48 150 21 FD 7.03PM 77.17PM 385 65 450 50 3 7,8 116 110 76 70 88 86 18 18 10 10 0.4 Y _ _  V  _  _
22 A22 22 52739 PRIMI 47 150 21 CPD 6.15PM 6.27PM 290 45 335 46 3 8,9 126 120 78 74 88 90 18 19 11 10 1.2 _ _ _ _ _ _
23 A23 30 52285 G2P1L1 50 148 23 Oligo 12.05PM 12.20PM 265 65 330 50 2 7,8 112 110 76 70 82 90 16 18 11 10 1.6 _ _  Y  Y
24 A24 24 52977 PRIMI 48 147 22 Oligo 11.48PM 12.01AM 285 46 331 46 3 7,8 116 110 82 78 88 90 17 17 10 10 0.6 _ _ _ _ _ _
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25 A25 20 52940 PRIMI 54 166 20 FD 2.50AM 3.04AM 275 46 321 40 3 8,9 120 122 78 80 84 80 18 18 10 9 0.4 _ _ _ _ _ _
26 A26 25 569 PRIMI 61 164 23 CPD 6.18PM 6.31PM 265 45 310 41 4 8,9 110 112 80 80 90 92 16 17 10 9 0.6 _
27 A27 25 1086 PRIMI 65 165 24 CPD 5.22PM 5.36PM 320 50 370 42 4 8,9 124 120 80 70 84 88 17 17 10 9 0.8 _ _ _ _ _ _
28 A28 30 1765 PRIMI 48 148 22 Breech 5.58PM 6.12PM 250 40 290 44 2 7,8 100 100 76 78 88 86 16 16 10 9 0.4 _ _ _ _ _ _
29 A29 21 2238 PRIMI 58 160 23 CPD 5.15PM 5.30PM 250 36 286 40 4 8,9 110 80 78 74 80 82 18 17 10 9 0.6 _ _ _ _ _ _
30 A30 28 260 G2P1L1 63 160 25 CPD 9.30AM 9.41AM 275 34 309 45 3 7,8 120 120 70 80 84 86 16 17 10 9 0.6 _ _ _ _ _ _
31 A31 23 1370 G2P1L1 50 160 20 Breech 11.35AM 11.501M 260 45 305 43 4 7,8 112 110 80 78 82 82 16 16 10 9 0.4 _ _ _  N  _  _
32 A32 23 1886 PRIMI 49 142 24 Breech 10.30AM 10.43AM 250 46 296 40 3 7,8 126 120 80 80 88 86 17 17 10 10 0.4 _ _ _ _ _ _
33 A33 23 2748 PRIMI 58 165 21 FD 4.50PM 5.06PM 240 46 286 45 3 8,9 110 110 70 70 86 84 16 17 11 10 1.2 _ _ _ _ _ _
34 A34 22 2762 PRIMI 57 153 24 Breech 7.54PM 8.06PM 265 35 300 42 3 7,8 120 120 78 76 84 82 17 18 11 11 0.8 _ _ _ _ _ _
35 A35 26 3763 PRIMI 52 153 22 FD 8.40PM 8.54P M 275 35 310 45 3 7,8 100 110 60 70 82 80 16 16 10 9 1.2 _ _ _ _ _ _
36 A36 25 4532 PRIMI 48 151 21 Oligo 3.30pm 3.45pm 265 35 300 44 3 7,8 110 118 76 74 84 86 17 17 10 9 1.2 _ _ _ _ _ _
37 A37 24 5936 G2P1L1 45 153 19 Oligo 9.45AM 10AM 245 43 288 47 3 7,8 110 118 84 84 90 92 16 17 9 9 0.4 _ _ _ _ _ _
38 A38 28 6718 PRIMI 52 162 20 CPD 9.36AM 9.50AM 260 38 298 42 3 8,9 118 116 84 80 78 76 17 16 11 10 0.6 _ _ _ _ _- _
39 A39 27 3894 PRIMI 62 161 24 FD 5.40PM 5.54PM 245 35 280 47 3 7,8 124 120 76 78 86 82 16 16 11 10 0.8 _ _ _ _ _ _
40 A40 24 3905 PRIMI 61 162 23 Obligue 6.35PM 6.50PM 275 45 320 42 4 7,8 110 110 82 80 76 76 18 17 11 10 0.6 _ _ V  _  _
41 A41 28 3921 G2P1L1 62 160 24 CPD 10.20PM 10.35PM 280 35 315 45 3 7,8 126 124 78 80 88 82 17 18 10 9 0.4 _ _ _ _ _ _
42 A42 20 4018 PRIMI 59 150 26 Oligo 10.33PM 10.48PM 265 40 305 40 3 7,8 110 114 80 78 82 80 16 16 11 10 0.8 _ _ _ _ _ _
43 A43 21 4881 PRIMI 52 157 21 FD 8.12AM 8.26AM 280 35 315 43 3 7,8 120 118 78 76 86 84 17 17 11 10 0.6 _ _ _ _ _ _
44 A44 25 4909 PRIMI 66 164 25 CPD 9.42PM 9.56PM 265 30 295 41 3 7,8 110 110 80 78 82 80 16 16 9 8 0.6 _ _ _ _ _ _
45 A45 27 5549 G2P1L1 44 148 20 Footling 1.40PM 1.55PM 240 45 285 46 4 7,8 124 120 82 80 84 82 18 17 11 10 0.4 _ _ _ _ _ _
46 A46 21 5610 PRIMI 61 165 22 CPD 11.42AM 11.56AM 260 40 300 43 3 8,9 110 110 70 70 76 74 16 17 10 9 0.6 _ _ _ _ _ _
47 A47 20 6167 PRIMI 60 161 23 FD 3.32pm 3.46pm 270 35 305 42 3 7,8 120 110 70 70 78 76 17 17 10 9 0.8 _ _ _ _ _ _
48 A48 25 6184 G2P1L1 53 157 22 FD 4.10PM 4.25PM 260 45 305 44 3 7,8 110 120 78 76 86 84 16 17 10 9 1.2 _ _ _  N  _  _
49 A49 23 6338 PRIMI 58 160 23 Oligo 5.24PM 5.38PM 240 50 290 40 3 8,9 120 120 70 70 80 82 17 17 10 9 0.8 _ _ _ _ _ _
50 A50 23 6247 PRIMI 57 158 23 FD 8.20PM 8.36PM 220 50 270 43 3 7,8 118 120 76 76 86 84 17 17 10 10 0.4 _ _ _ _ _ _
51 A51 30 6341 G2A1 57 159 23  Brow pres 11.19AM 11.37AM 240 35 275 40 3 7,8 110 120 80 70 88 90 16 16 11 10 1 _ _ _ __ _ _
52 A52 27 6594 PRIMI 58 162 22 FD 11PM 11.15PM 275 45 320 43 3 7,8 120 110 76 74 86 86 16 17 11 10 0.8 _ _ _ _ _ _
53 A53 30 6967 PRIMI 58 160 23 CPD 5.07PM 5.24PM 260 50 310 44 3 7,8 126 120 80 80 90 18 18 17 11 10 0.8 _ _ _ _ _ _
54 A54 20 7307 PRIMI 62 162 24 FD 5.56PM 6.12PM 250 50 300 45 3 8,9 120 110 82 80 90 90 18 18 10 9 0.6 _ _ _ _ _ _
55 A55 26 7552 G2P1L1 60 161 23 PL/PROM 6.45PM 7PM 265 45 310 43 3 7,8 130 126 78 80 84 86 17 17 10 9 0.8 _ _ _ _ _ _
56 A56 25 7672 G2P1L0 55 161 21 FD 5.57PM 6.13PM 245 50 295 42 3 7,8 126 120 78 70 88 86 16 16 11 10 0.4 _ _ _ _ _ _
57 A57 23 7797 PRIMI 57 159 23 CPD 6.10PM 6.24PM 280 40 320 40 3 7,8 110 110 80 70 86 80 17 18 11 10 1 _ _ _  N  _  _
58 A58 27 8003 G2P1L1 64 166 23 FD 8.22PM 8.38PM 245 40 285 40 4 7,8 118 112 70 70 84 88 16 16 10 9 1.2 _ _ _ _ _ _
59 A59 22 7930 PRIMI 45 153 19 FD 9.15PM 9.30PM 245 35 280 43 3 7,8 116 110 70 70 76 80 18 17 10 9 0.6 _ _ _ _ _ _
60 A60 26 8025 G2A1 52 157 21 FD 5.32PM 5.50PM 265 35 300 42 3 7,8 110 100 76 70 78 76 17 17 10 9 0.8 _ _ _ _ _ _
61 A61 24 8361 PRIMI 58 160 23 FD 4.28PM 4.42PM 280 30 310 45 28 7,8 120 120 70 70 78 76 16 16 11 10 0.8 _ _ _ _ _ _
62 A62 27 8368 PRIMI 55 161 21 FD 6.35PM 6.52PM 265 50 315 42 3 7,8 124 120 78 80 80 82 18 17 11 10 1 _ _ _ _ _ _
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63 A63 23 8335 PRIMI 58 150 26 CPD 4.15PM 4.30PM 250 35 285 43 4 8,9 112 110 70 70 84 86 18 17 10 10 0.8 _ _ _ _ _ _
64 A64 27 8652 PRIMI 53 157 22 Breech 2.35PM 2.50PM 260 35 295 40 2 7,8 116 110 76 76 90 92 16 16 11 10 1.2 _ _ _ _ _ _
65 A65 24 8600 G2P1L1 58 160 23 Breech 6.35PM 6.50PM 275 30 305 42 3 6,7 118 116 76 78 88 84 17 17 10 9 0.4 _ _ _ _ _ _
66 A66 20 8575 G2A1 61 150 27 Oligo 5.40PM 5.56PM 280 40 320 44 3 6,7 118 120 80 80 90 86 18 18 10 9 0.6 _ _ _ _ _ _
67 A67 28 9559 G2P1L1 44 148 20 FD 10.25PM 10.41PM 260 35 295 43 3 7,8 120 118 76 74 76 78 16 17 10 9 0.6 _ _ _ _ _ _
68 A68 23 10441 PRIMI 61 168 22 Breech 10.45PM 11PM 280 50 330 42 3 7,8 110 120 76 76 80 76 17 17 10 9 1 _ _ _ _ _ _
69 A69 23 10750 PRIMI 55 155 23 Oligo 5.40PM 5.56PM 275 45 320 45 3 7,8 110 120 70 72 88 90 16 16 10 9 1.2 _ _ _ _ _ _
70 A70 22 10751 PRIMI 72 168 26 Oligo 4.57PM 5.13PM 270 40 310 41 3 6,7 120 110 80 80 80 86 18 17 9 9 0.4 _ _ _ _ _ _
71 A71 25 11720 PRIMI 62 161 24 FD 5.56PM 6.12PM 275 45 320 40 2 6,7 130 120 78 78 84 86 16 17 10 9 0.4 _ _ _ _ _ _
72 A72 20 12066 PRIMI 67 168 24 FD 7.20PM 7.35PM 350 70 420 43 3 7,8 112 120 70 70 80 84 17 16 11 9 1.8 Y _ _  V  _  _
73 A73 25 12251 PRIMI 52 162 20 Face 2.45PM 3PM 250 40 290 43 3 7,8 120 110 78 76 76 78 18 17 11 10 0.8 _ _ _ _ _ _
74 A74 22 12390 G2P1L0 70 168 25 Breech 9.20PM 9.35PM 245 40 285 45 3 6,7 100 100 60 60 90 94 17 18 11 10 1.2 _ _ _ _ _ _
75 A75 25 12555 PRIMI 48 150 21 Oligo 5.35PM 5.52PM 240 42 282 40 3 7,8 110 110 70 70 78 76 16 17 12 11 1 _ _ _ _ _ _
76 A76 25 12572 G2P1L1 49 160 19 FD 12.45PM 1PM 250 22 272 41 3 6,7 122 120 76 78 80 82 16 16 10 9 0.6 _ _ _ _ _ _
77 A77 24 12819 G2A1 58 160 23 Oligo 4.25PM 4.41PM 265 45 310 42 3 6,7 132 126 80 78 88 90 17 17 10 10 0.8 _ _ _ _ _ _
78 A78 25 13224 G2P1L1 55 163 21 Face 2.05PM 2.26PM 270 30 300 45 3 7,8 120 120 74 74 74 76 16 16 10 10 0.8 _ _ _ _ _
79 A79 24 13800 PRIMI 60 158 24 FD 5.10PM 5.26PM 300 26 326 45 2 7,8 126 126 74 70 78 78 17 18 11 10 1.2 _ _ _ _ _ _
80 A80 24 16644 PRIMI 64 168 23 FD 3.35PM 3.50PM 245 35 280 43 3 6,7 126 120 70 70 80 76 17 16 10 9 0.4 _ _ _ _ _ _
81 A81 20 16942 PRIMI 48 150 21 CPD 6.05PM 6.20PM 250 30 280 46 4 7,8 130 126 80 78 88 86 18 18 10 10 0.4 _ _ _ _ _ _
82 A82 26 17245 PRIMI 52 166 19 FD 6.05PM 6.24PM 225 35 260 43 3 6,7 114 110 78 80 90 92 18 17 11 11 0.8 _ _ _  N  _  _
83 A83 24 16452 PRIMI 52 159 21 FD 9.15PM 9.40PM 240 36 276 43 3 6,7 116 118 68 70 86 84 17 17 10 10 0.4 _ _ _ _ _ _
84 A84 24 17378 G2P1L1 54 153 23 FD 10.25AM 10.43AM 245 36 281 42 2 7,8 120 120 70 70 90 88 18 17 11 9 0.8 _ _ _ _ _ _
85 A85 27 18202 PRIMI 55 154 23 CPD 4.30PM 4.56PM 250 54 304 44 3 7,8 110 120 70 68 92 94 18 17 10 9 0.6 _ _ _ _ _ _
86 A86 20 18935 PRIMI 60 159 24 FD 5.05PM 5.22PM 245 40 285 43 3 6,7 114 118 78 80 92 96 16 16 10 10 0.4 _ _ _ _  Y  _
87 A87 20 18979 PRIMI 61 162 23 FD 10.15PM 10.32PM 250 28 278 45 3 7,8 120 110 80 80 90 90 17 16 11 10 0.8 _ _ _ _ _ _
88 A88 25 19813 G2P1L1 54 166 20 FD 9.20PM 9.37PM 240 35 275 44 3 7,8 130 120 76 70 82 84 16 17 11 10 0.8 _ _ _ _ _ _
89 A89 27 20171 G2A1 55 159 21,8 CPD 3.15PM 3.30PM 235 35 270 42 3 7,8 116 120 70 70 92 88 17 17 11 11 0.4 _ _ _ _ _ __
90 A90 20 20776 PRIMI 72 166 26 FD 4.10PM 4.25PM 235 44 279 45 3 8,9 118 120 70 72 78 76 17 18 10 9 0.6 _ _ _ _ _ _
91 A91 23 21655 G2P1L1 55 159 22 FD 2.56PM 3.10PM 240 40 280 43 3 7,8 120 118 86 80 92 88 18 17 10 9 0.8 _ _ _ _ _ _
92 A92 21 21637 PRIMI 67 166 24 CPD 7.15PM 7.33PM 250 35 285 43 3 7,8 110 116 80 78 80 82 18 17 10 9 1 _ _ _  D  _  _
93 A93 25 22399 PRIMI 58 159 23 FD 7PM 7.15PM 250 35 285 45 3 6,7 110 110 80 80 84 88 17 16 11 10 1 _ _ _ _ _ _
94 A94 21 22738 G2P1L1 56 166 20 CPD 4PM 4.15PM 245 40 285 46 3 6,7 120 120 76 78 94 96 16 17 11 10 0.6 _ _ _ _ _ __
95 A85 28 21577 PRIMI 64 166 23 FD 10.05PM 10.23PM 230 35 265 42 3 7,8 120 118 84 80 86 84 17 18 10 10 0.6 _ _ _ _ _ _
96 A96 23 23009 PRIMI 54 159 21 FD 6.40PM 6.56PM 250 35 285 50 3 6,7 118 120 76 78 80 82 16 17 11 10 0.8 _ _ _ _ _ _
97 A97 23 24309 PRIMI 58 166 21 FD 4.40PM 4.56PM 245 35 280 40 2 7,8 110 110 70 70 84 86 16 16 10 9 0.8 _ _ _ _ _ _
98 A98 24 24316 PRIMI 60 150 27 FI 3.15PM 3.30PM 230 45 275 41 3 7,8 110 110 82 82 0 88 18 17 10 9 0.6 _ _ _ _ _ _
99 A99 27 24309 PRIMI 60 153 26 FI 7.32PM 7.48PM 240 30 270 41 3 6,7 120 110 78 80 94 96 17 17 10 9 1.2 _ _ _ _ _ _
100 A100 22 24507 PRIMI 60 152 26 FI 8PM 8.17PM 250 35 285 40 3 7,8 126 124 70 70 90 92 17 18 10 9 0.8 _ _ _ _ _ _
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101 B1 23 47609 PRIMI 60 158 24 CPD _ 11.55AM 320 60 380 43 3.5 7,8 110 112 78 76 90 92 17 17 11 10 1 _ _ _ _ _ _
102 B2 30 47786 PRIMI 56 150 24.9 Precious _ 10.26PM 340 60 400 40 2.7 7,8 120 120 80 78 86 88 16 17 12 10 1.6 _ _ _ _ _ _
103 B3 22 47474 PRIMI 57 165 20.9 Breech _ 12.02PM 370 70 440 45 3.5 6,7 110 110 70 70 88 86 18 17 10 9 1.2 _ _ _ _ _ _
104 B4 30 48156 PRIMI 56 152 24.2 Precious _ 6.25PM 360 60 420 45 3 7,8 120 118 76 78 86 86 17 17 10 9 0.8 _ _ _ _ _ _
105 B5 23 48275 PRIMI 60 162 22.9 OLIGO _ 11.02PM 350 60 410 44 3.6 7,8 110 110 78 76 80 86 17 18 9 9 0.6 _ _ _ V _ _
106 B6 24 48353 PRIMI 48 140 24.5 FD _ 1AM 360 40 400 41 3.7 6,7 130 126 80 78 78 76 17 17 11 9 1.2 _ _ _ _ _ _
107 B7 23 48806 PRIMI 60 150 26.7 Breech _ 7PM 340 70 410 45 3.2 6,7 124 120 80 80 86 90 18 18 11 11 0.8 _ _ _ _ _ _
108 B8 21 48650 PRIMI 54 153 23.1 FD _ 11.50PM 700 120 820 50 3.3 6,7 110 100 84 80 76 80 17 17 11 9 2 Y Y Y _ _ _
109 B9 20 49316 PRIMI 61 162 23.2 Breech _ 6.42PM 380 60 440 46 2.5 7,8 120 110 80 80 78 80 17 18 12 11 1 _ _ _ _ _ _
110 B10 28 49500 PRIMI 48 153 20.5 Breech _ 12.05PM 360 80 440 40 2.3 7,8 110 112 78 78 88 90 16 16 12 10 1.2 _ _ _ _ _ _
111 B11 27 50926 PRIMI 62 158 24.8 FD _ 12.25PM 380 80 460 40 3 7,8 110 110 86 84 90 92 16 17 11 9 1.6 _ _ _ _ _ _
112 B12 23 51175 PRIMI 58 146 27.2 FD _ 6PM 370 75 445 38 2.6 6,7 114 120 86 80 84 80 17 17 10 10 0.4 _ _ _ _ _ _
113 B13 27 48173 G2P1L1 63 150 28 FD _ 11.48AM 360 80 440 42 2.8 6,7 110 110 80 80 88 84 16 18 10 9 0.8 _ _ _ N Y _
114 B14 24 49230 G2P1L1 58 161 22.4 CPD _ 10.35AM 350 80 430 45 3.2 6,7 120 116 70 70 84 88 17 16 9 9 0.4 _ _ _ _ _ _
115 B15 23 49266 G2P1L1 61 150 27.1 CPD _ 10.54AM 365 85 450 44 3.5 7,8 124 120 70 74 76 80 18 17 10 9 0.8 _ _ _ _ _ _
116 B16 25 49775 G2P1L1 48 150 21.3 CPD _ 11.40AM 370 70 440 42 3 6,7 110 114 84 82 80 80 16 16 11 10 1.2 _ _ _ _ _ _
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117 B17 27 50582 PRIMI 56 157 22.7 CPD _ 10.06AM 375 90 465 41 3.2 6,7 120 110 82 80 78 76 17 17 12 10 1.6 _ _ _ _ _ _
118 B18 24 51457 PRIMI 53 153 22.6 Breech _ 9.47AM 370 70 440 44 3.2 7,8 120 118 80 82 76 80 18 17 11 10 1 _ _ _ _ _ _
119 B19 23 51846 G2A1 60 161 23.1 CPD _ 10.40AM 365 105 470 43 4.1 7,8 110 110 70 70 88 90 17 17 11 10 1 _ _ _ _ _ _
120 B20 27 50097 PRIMI 48 152 20.8 OLIGO _ 5.45PM 345 80 425 40 3 7,8 110 114 70 70 84 84 16 17 10 9 0.6 _ _ _ _ _ _
121 B21 21 51931 PRIMI 56 151 24.6 CPD _ 10.33AM 380 100 480 42 3.2 8,9 116 116 74 76 88 86 17 17 11 10 1.4 Y _ _ V _ _
122 B22 20 52057 PRIMI 52 154 21.9 FD _ 11AM 360 85 445 38 2.8 7,8 128 130 76 78 80 84 16 16 11 10 0.8 _ _ _ _ _ _
123 B23 26 52551 PRIMI 51 153 21.8 FD _ 12.05PM 360 90 450 40 2.8 6,7 110 110 80 76 82 80 18 18 9 9 0.4 _ _ _ _ _ _
124 B24 24 52197 PRIMI 62 150 27.6 FD _ 3AM 390 90 480 42 3.2 6,7 126 122 84 86 78 78 16 17 10 8 1.2 _ _ _ _ _ _
125 B25 21 52940 PRIMI 54 153 23.1 FD _ 8.05A M 375 85 460 38 3.1 6,7 130 122 78 76 82 84 17 17 11 11 0.6 _ _ _ _ _ _
126 B26 30 131 G2P1L1 58 162 22.1 PL/PROM _ 5.45AM 360 70 430 48 2.8 6,7 120 126 78 78 78 80 18 17 11 10 1.2 _ _ _ _ _ _
127 B27 24 575 PRIMI 55 143 26.9 CPD _ 7.05PM 430 75 505 42 3.5 6,7 120 116 74 74 80 80 17 18 11 9 1.8 Y _ Y _ _ Y
128 B28 23 1052 PRIMI 55 155 22.9 FD _ 12.45PM 370 80 450 43 3.5 7,8 110 110 78 76 92 90 18 18 12 10 1.6 _ _ _ _ _ _
129 B29 28 2249 PRIMI 55 153 23.5 FD _ 7.20PM 350 80 430 45 2.9 7,8 110 110 70 70 86 86 17 17 10 9 0.6 _ _ _ _ _ _
130 B30 25 4111 G2P1L1 64 150 28.4 CPD _ 10AM 370 95 465 45 3 7,8 120 122 78 80 80 78 16 16 11 10 0.8 _ _ _ _ _ _
131 B31 29 1462 G2P1L1 48 149 21.6 FD _ 11.15AM 360 90 450 38 2.8 7,8 116 118 80 86 86 80 16 16 11 10 0.8 _ _ _ _ _ _
132 B32 28 2076 G2P1L1 58 162 22.1 PL/PROM _ 10.15AM 365 90 455 46 2.7 6,7 120 126 86 90 80 80 17 17 11 10 1.2 _ _ _ _ _ _
133 B33 23 3256 PRIMI 48 141 24.1 FD _ 9.30AM 360 85 445 44 2.5 6,7 130 120 78 84 86 84 17 18 2 10 1.2 _ _ _ _ _ _
134 B34 23 3289 G2P1L1 60 162 22.9 FD _ 12.32PM 375 80 455 45 3 6,7 120 116 80 80 80 82 17 17 10 9 0.8 _ _ _ _ _ _
135 B35 24 3166 PRIMI 58 168 20.5 OLIGO _ 8.05PM 360 70 430 43 2.2 5,6 120 110 78 76 78 80 17 16 10 9 1.2 _ _ _ _ Y Y
136 B36 25 3303 G2A1 57 161 22 FD _ 11.50AM 370 85 455 46 3.3 6,7 110 110 80 82 80 88 17 17 11 9 1.2 _ _ _ _ _ _
137 B37 30 5192 G2P1L1 56 168 19.8 PL/CPD _ 10.45AM 360 70 430 48 3.2 6,7 120 120 70 70 76 78 17 17 11 10 1.2 _ _ _ _ _ _
138 B38 24 5228 G2P1L1 63 160 24.6 PL/CPD _ 10.15AM 360 90 450 49 3.5 6,7 110 110 78 76 80 84 16 16 10 9 0.8 _ _ _ _ _ _
139 B39 24 4016 PRIMI 69 148 31.5 FD _ 9.45PM 370 80 450 42 3.6 7,8 110 110 76 78 80 76 17 18 10 9 1 _ _ _ _ _ _
140 B40 24 4120 G2P1L1 40 135 21.9 PL/PROM _ 6.35AM 360 80 440 41 2.8 7,8 126 120 78 78 78 80 16 16 12 11 0.6 _ _ _ _ _ _
141 B41 27 4289 PRIMI 44 148 20.1 FD _ 12.45AM 350 70 420 40 3.3 7,8 120 110 80 80 78 78 17 17 11 9 1.2 _ _ _ _ _ _
133
142 B42 21 4954 PRIMI 63 152 27.3 FD _ 6.40AM 370 90 460 43 3.2 6,7 120 118 78 80 90 92 18 17 10 9 0.6 _ _ _ _ _ _
143 B43 27 4989 G2P1L1 55 168 19.1 FD _ 6AM 740 80 820 43 3.6 6,7 114 116 76 78 90 94 18 17 11 9 1.6 Y Y Y _ _ _
144 B44 21 5773 PRIMI 53 157 21.5 FD _ 1AM 310 70 380 45 2.4 6,7 120 122 80 80 88 86 17 17 11 10 0.8 _ _ _ _ _ _
145 B45 24 5797 G2P1L1 54 167 19.4 PL/CPD _ 10.20AM 350 85 435 40 3.5 6,7 124 120 78 80 80 84 16 17 11 10 0.6 _ _ _ _ _ _
146 B46 22 6186 PRIMI 40 140 20.4 CPD _ 3.35PM 370 95 465 44 3.4 7,8 116 120 80 80 84 82 16 17 12 11 1.2 _ _ _ _ _ _
147 B47 24 6260 G2P1L0 60 161 23.1 Breech _ 9.50AM 365 80 445 43 3 6,7 120 118 78 80 80 78 17 17 12 10 0.6 _ _ _ _ _ _
148 B48 30 6338 PRIMI 54 166 19.6 FD _ 7.56PM 365 70 435 41 2.6 6,7 118 120 78 70 78 80 17 18 10 9 1.2 _ _ _ _ _ _
149 B49 24 10373 G2P1L1 48 150 21.3 FD _ 12.45AM 360 70 430 42 2.8 7,8 106 100 76 78 86 82 18 18 11 9 1.2 _ _ _ _ _ _
150 B50 21 6997 PRIMI 61 164 22.7 Breech _ 5.55PM 370 65 435 36 2.8 7,8 120 122 78 80 80 80 17 18 10 9 1 _ _ _ _ _ _
151 B51 24 7292 PRIMI 46 148 21 FD _ 12.25PM 370 70 440 46 2.8 8,9 118 120 78 80 78 80 17 17 12 10 1.2 _ _ _ _ _ _
152 B52 20 7380 PRIMI 55 155 22.9 CPD _ 11.50AM 375 70 445 44 3.5 7,8 120 122 86 80 76 76 16 16 11 9 1.2 _ _ _   _
153 B53 21 7711 PRIMI 59 149 26.6 FD _ 1.221M 375 80 455 36 2.2 7,8 116 110 88 84 80 80 17 17 9 8 1.4 _ _ _ _ _ _
154 B54 24 7696 G2P1L1 70 152 30.3 FD _ 6.25PM 350 70 420 40 2.3 7,8 110 110 70 70 82 80 16 16 12 11 0.8 _ _ _ _ _ _
155 B55 24 8165 G2P1L1 59 148 26.9 Breech _ 10AM 360 95 455 42 1.7 7,8 120 110 80 80 86 88 17 18 12 10 1.2 _ _ _ _ Y Y
156 B56 25 8181 PRIMI 62 165 22.8 FD   10.35AM 360 70 430 46 2.8 7,8 130 128 80 70 90 78 18 18 10 9 1 _ _ _ _ _ _
157 B57 27 8270 G2A1 58 148 26.5 FD _ 12.05PM 355 70 425 45 3 6,7 110 120 86 70 78 80 17 18 9 9 0.4 _ _ _ _ _ _
158 B58 21 8366 PRIMI 57 148 26 FD _ 6.55PM 375 70 445 42 3.7 7,8 120 110 70 70 84 88 17 17 9 9 0.6 _ _ _ V _ _
159 B59 28 8963 PRIMI 58 160 20.7 FI _ 7.12PM 380 55 435 43 2.3 7,8 110 110 76 74 90 90 18 17 11 10 0.8 _ _ _ _ _ _
160 B60 30 9393 G2P1L1 56 148 25.6 Breech _ 6.13PM 680 60 740 45 3 7,8 116 120 78 80 84 82 18 18 11 9 1.8 Y Y Y _ _ _
161 B61 24 9348 PRIMI 40 138 21 CPD _ 6.50AM 370 60 430 45 3.7 7,8 100 112 70 70 78 78 17 18 12 11 1 _ _ _ _ _ _
162 B62 24 9683 PRIMI 61 162 23.2 FD _ 12.05AM 365 75 440 46 2.8 7,8 110 100 80 80 86 84 17 17 10 9 1.2 _ _ _ _ _ _
163 B63 23 10440 PRIMI 48 146 22.5 FD _ 12.20AM 350 75 425 42 3.5 7,8 120 110 76 70 88 84 18 18 13 11 1.2 _ _ _ _ _ _
164 B64 25 11688 PRIMI 67 153 28,6 FD _ 6.35PM 370 50 420 42 2.9 7,8 108 100 78 80 76 78 16 16 11 11 0.8 _ _ _ _ _ _
165 B65 22 11435 PRIMI 63 160 24.6 Breech _ 11.25AM 360 65 425 40 2.8 6,7 100 90 70 70 80 80 17 17 10 9 0.8 _ _ _ _ _ _
166 B66 23 12186 PRIMI 48 143 23.5 FD _ 11.25AM 375 75 450 44 2.5 8,9 130 120 80 84 76 76 16 16 9 9 0.4 _ _ _ _ _ _
134
167 B67 26 12466 G2P1L0 65 153 27.8 OLIGO _ 5.23PM 355 70 425 43 3.3 7,8 110 116 76 76 80 76 16 17 12 11 1.2 _ _ _ _ _ _
168 B68 26 12209 G2P1L1 63 166 22.9 FD _ 11.23AM 370 70 440 45 2.7 7,8 110 100 86 84 78 78 18 18 10 9 0.8 _ _ _ _ _ _
169 B69 24 12583 PRIMI 56 158 22.4 OLIGO _ 5.52PM 365 85 450 46 2.6 7,8 100 110 88 90 80 82 18 17 12 12 0.8 _ _ _ _ _ _
170 B70 26 12802 G2A1 63 158 22.2 OLIGO _ 12.15PM 365 65 430 40 3.8 7,8 110 110 78 80 82 80 17 17 11 10 0.6 _ _ _ _ _ _
171 B71 24 13013 G2A1 63 153 26.9 FD _ 4.10PM 355 70 425 42 3.3 6,7 130 126 80 70 94 92 17 18 11 11 0.8 _ _ _ _ _ _
172 B72 27 13808 PRIMI 62 160 24.2 CPD _ 7PM 370 80 450 43 3.2 8,9 136 128 86 80 90 90 19 18 11 10 0.6 _     _ _ _
173 B73 20 14494 PRIMI 63 159 24.9 FD _ 3.52PM 375 90 465 44 3.5 7,8 128 122 86 80 90 94 17 18 11 10 1.2 _ _ _ _ _ _
174 B74 25 14281 PRIMI 61 153 26.1 OLIGO _ 5.46PM 400 70 470 46 2.9 8,9 110 110 70 70 78 74 18 18 12 10 1.4 Y _ Y V _ _
175 B75 21 16464 PRIMI 61 162 23.2 FD _ 7.26AM 375 75 450 43 3.3 7,8 120 120 70 70 86 90 19 18 10 10 0.8 _ _ _ _ _ _
176 B76 27 16487 G2P1L1 58 153 24.8 OLIGO _ 11.15PM 360 70 430 42 2.8 7,8 100 100 76 70 76 76 18 17 10 9 0.6 _ _ _ _ _ _
177 B77 21 16744 PRIMI 68 166 24.7 FD _ 4PM 365 65 430 42 2.8 7,8 120 110 80 80 78 76 18 18 12 12 0.6 _ _ _ _ _ _
178 B78 23 17202 PRIMI 60 146 28.1 CPD _ 5.45PM 385 60 445 43 3 7,8 116 118 74 76 76 80 17 17 10 8 1.2 _ _ _ _ _ _
179 B79 28 17529 G2P1L1 57 161 22 FD _ 11.55AM 355 80 435 40 2.4 6,7 130 130 78 70 70 70 17 18 11 10 0.8 _ _ _ _ _ _
180 B80 26 18015 PRIMI 58 147 26.8 FD _ 2.33PM 360 80 440 41 2.4 6,7 120 120 70 70 86 84 18 18 11 10 1.2 _ _ _ _ _ _
181 B81 21 17983 PRIMI 51 162 19.4 FI _ 10.35PM 375 65 440 40 2.9 7,8 100 100 70 60 84 88 16 17 10 9 0.6 _ _ _ _ _ _
182 B82 23 18153 PRIMI 57 161 22 FD _ 11.03AM 700 60 760 43 3 7,8 120 110 80 80 90 90 16 16 11 9 2.2 Y Y Y _ _ _
183 B83 25 18520 PRIMI 60 148 27.4 FD _ 1.06PM 365 55 420 42 2.8 7,8 124 120 78 80 82 80 17 18 10 9 1.2 _ _ _ _ _ _
184 B84 21 18806 PRIMI 65 165 23.9 FD _ 1.27PM 360 80 440 40 2.6 6,7 116 118 76 78 88 86 16 17 11 10 1 _ _ _ _ _ _
185 B85 26 19815 G2P1L1 61 146 28.6 FD _ 5.45PM 350 65 415 40 2.8 6,7 100 100 80 80 80 82 17 17 10 9 0.6 _ _ _ _ _ _
186 B86 25 19817 PRIMI 58 148 26.5 FI _ 10.07PM 365 85 450 43 3.5 6,7 110 100 80 70 88 84 17 18 10 9 1.2 _ _ _ _ _ _
187 B87 28 20201 G2P1L1 48 166 17.4 PL/PROM _ 1.13PM 360 55 415 42 2.6 6,7 120 120 78 80 80 78 16 16 10 9 0.6 _ _ _ _ _ _
188 B88 22 20038 PRIMI 55 141 27.7 FD _ 6.56PM 350 50 400 41 3.1 7,8 118 120 80 78 80 80 17 17 11 10 0.8 _ _ _ _ _ _
189 B89 23 20356 PRIMI 52 143 25 CPD _ 5.46PM 360 45 405 44 3.3 7,8 100 70 80 60 78 78 16 16 10 9 1 _ _ _ _ _
190 B90 26 21448 PRIMI 56 158 22.4 FD _ 7.55PM 355 70 425 43 3 6,7 130 120 80 70 78 80 17 17 12 11 0.8 _ _ _ _ _ _
191 B91 23 21636 PRIMI 55 144 26.5 FD _ 10.52PM 360 55 415 42 3.2 6,7 124 120 86 88 84 84 18 17 10 9 0.8 _ _ _ _ _ _
135
192 B92 30 21750 G2P1L1 68 156 27.9 PL/CPD _ 10.25AM 360 75 435 42 2.9 6,7 110 120 80 86 90 90 17 18 10 9 1 _ _ _ _ _ _
193 B93 26 22399 G2P1L1 55 148 25.1 PL/PROM _ 12.55PM 375 50 425 44 2.3 7,8 120 110 70 70 84 82 17 17 12 11 1.2 _ _ _ _ Y _
194 B94 21 22738 PRIMI 58 146 27.2 FD _ 11.32AM 360 40 400 41 3 6,7 130 126 78 80 82 80 17 17 10 10 0.8 _ _ _ _ _ _
195 B95 22 23154 G2P1L1 54 145 25.7 CPD _ 2.13PM 690 165 855 41 3 7,8 100 110 80 80 86 86 16 17 11 9 2.4 Y Y Y   _ Y
196 B96 24 23745 PRIMI 58 160 20.7 FI _ 10.05PM 380 55 435 40 3.2 7,8 110 110 70 70 84 88 18 17 11 10 0.8 _ _ _ _ _ _
197 B97 25 24122 G2P1L1 67 145 31.9 FD _ 7.34PM 365 50 415 40 3 7,8 120 120 80 70 88 88 17 17 10 9 0.6 _ _ _ _ _ _
198 B98 22 24157 G2P1L1 63 156 25.9 PL/PROM _ 6.30PM 320 45 365 41 2.5 6,7 110 120 78 80 76 78 16 16 10 9 1.2 _ _ _ _ _ _
199 B99 27 24440 PRIMI 55 146 25.8 OLIGO _ 6.24PM 380 60 440 41 3 6,7 100 100 70 60 80 82 18 17 10 9 1 _ _ _ _ _ _
200 B100 27 24512 PRIMI 61 148 27.8 FD _ 5PM 360 65 425 43 2.7 7,8 110 110 80 80 78 80 17 18 10 9 0.8 _ _ _ _ _ _
Note:
Y-Yes
N-Nausea
V-Vomiting
D-Diarrhea
